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Reactive oxygen species (ROS) are formed continuously in living cells 
as a consequence of normal metabolic and biochemical reactions as well as 
in pathological conditions. Although some ROS have important physiological 
functions, they nevertheless, have a wide potential for causing cell injury. 
The oxidative damage caused to DNA is an important factor in mutagenesis 
and carcinogenesis. Among the ROS, 'OH radical is the most damaging and 
can virtually react with any macromolecule it encounters. In vivo, hydroxyl 
radicals are formed by ionizing radiations or through the Haber-Weiss or 
Fenton reactions. The hydroxyl radical, thus generated, causes DNA damage 
leading to strand breaks, base damage and conformational changes. 
Commercially available calf thymus DNA was purified free of proteins 
and single-stranded regions and digested with micrococcal nuclease to obtain 
fragments of about 70 - 800 bp. Aqueous solutions of native and 400 bp DNA 
were irradiated by UV light (254 nm) in the presence of hydrogen peroxide. 
Chemical alterations induced in DNA following modification by *0H, were 
studied by thermal denaturation, sedimentation in alkaline sucrose density 
g rad i en t , nuc lease SI d iges t ib i l i ty and h y d r o x y a p a t i t e column 
chromatography. Modified DNA samples showed a marked hypochromicity at 
260 nm over the unmodified DNA, reflecting the modification of bases in 
ROS-DNA. 
The Tm of native ROS-DNA was determined to be 81°C, while that of 
nDNA was found to be 87.5°C, showing a net decrease of 6.5°C. The Tm of 
400 bp-ROS-DNA was 73°C and that of its unmodified counterpart was 
87.5°C. The genera t ion of single strand breaks was r e i t e ra t ed by 
i i 
hydroxyapati te column chromatography and nuclease SI digestibil i ty. 
Hydroxyl radical was found to induce DNA base modifications, which was 
quantified by ion exchange chromatography on DEAE Sephadex A-25. In the 
case of ROS-DNA, all the four bases were found to be modified. Thymine 
was modified the most (46.8%), followed by guanine (30.6%), cytosine 
(19.8%) and adenine (16.7%). In case of 400 bp ROS-DNA as well, the 
modification of thymine was maximum (58.3%). 
Native ROS-DNA was used to induce antibodies in goat. The ROS-
DNA was found to be a potent immunizing stimulus, inducing high titre 
antibodies. The antigenic specificity of the induced antibodies was studied 
by competition ELISA. The immunogen showed a high degree of specificity 
for the induced antibodies. In addition, the antibodies also showed a 
considerable recognition of native DNA. The results indicate the recognition, 
in part, of some antigenic determinant common to both ROS-modified and 
nDNA, which could be the sugar-phosphate backbone of the nucleic acids. 
Adenine, thymine and homopolymers poly(dA) and poly(dT) and their 
ROS-modified forms were also used as inhibitors in competition ELISA. It 
was observed that adenine, ROS-adenine and thymine showed negligible 
inhibition, while ROS-poly(dA) showed a high degree of inhibition. However, 
of special interest was the inhibition of 53% and 59% by ROS-thymine and 
ROS-poly(dT). The data clearly indicates the recognition of epitopes 
generated o- thymine and poly(dT) after ROS-modification. The induced 
antibodies showed a broad spectrum of reactivity as indicated by their 
binding to synthetic polynucleotides. The antibodies showed inhibitions of 
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55%, 5 1 % and 48 .5% respectively with poly(dG).poly(dC), poly(dA-
dC).poly(dG-dT) and poly(dG-dC).poly(dG-dC), while poly(dI-dC).poly(dI-
dC) and poly(rG).poly(dC) were non-inhibitory. The binding of the antibodies 
to ROS-DNA and nDNA was also ascertained by band shift assay. 
Monoclonal antibodies were generated against 400 bp ROS-DNA. A 
high binding monoclonal (PjC^jD^) was chosen for this study. The monoclonal 
antibody showed a high inhibition in its activity, to the extent of 84% when 
ROS-DNA was used as inhibitor and a lower inhibition of 60% with 200 bp 
ROS-DNA. The antibody also showed cross-reactivity with nDNA, showing 
an inhibition of 65%. 
The fine antigenic specificity of the monoclonal antibodies was studied 
by competition ELISA, using nitrogenous bases, homopolynucleotides and 
their ROS-modified forms as competitors.. Thymine, thymidine, adenine, 
ROS-adenine, cytosine, ROS-cytosine and guanine showed negligible 
inhibition. In contrast , ROS-thymine, ROS-thymidine and ROS-guanine 
showed high inhibitions of 66.5%, 57% and 48% respectively. Poly(dA), 
ROS-poIy{dA), poly(G) and poly(dT) were non-inhibitory of monoclonal 
antibody binding to ROS-DNA. However, ROS-poly(dT) was observed to be 
an effective inhibitor showing a maximum inhibition of 68%, while inhibition 
by ROS-poly(G) was 47%. 
The reactivity or recognition of native and ROS-DNA by antibodies in 
the sera of healthy, normal humans of different age groups was studied by 
competition ELISA. Sera from the control or the young age population 
showed negligible reactivity towards the two polymers. In contrast, three 
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sera from individuals in the age group 50-59 years showed a high binding 
to ROS-DNA with maximum inhibitions of 43-47%, while one serum showed 
greater reactivity with nDNA. Similarly, sera from the age group over 60 
years showed greater reactivity for ROS-DNA. Four sera showed high 
inhibitions of >60% with ROS-DNA as inhibitor, while the inhibition was in 
the range of 55-60% with nDNA. One serum showed a moderate binding to 
ROS-DNA, while one recognized nDNA better than ROS-DNA. The data 
indicates a definite increase in the levels of antibodies reacting with ROS-
DNA and nDNA, with a higher recognition of oxidatively damaged DNA with 
advancing age. 
Monoclonal anti-ROS-DNA antibody was used as a molecular probe to 
detect oxidative DNA damage in normal healthy individuals. DNA was isolated 
from lymphocytes of normal human subjects of varying age groups. The 
isolated DNA was used as inhibitor in a competition ELISA. The results 
indicate a low recognition of DNA from young age groups (<35 and 35-49 
years) by the monoclonal antibody. In the age group 50-59 years, one DNA 
isolate showed a high inhibition (57%) of monoclonal antibody binding to 
solid-phase antigen, while four more samples showed lower inhibitions of 
40-42% and three samples were negative. In the age group above 60 years, 
four DNA samples were recognized to a great extent by the monoclonal 
antibody, giving an inhibition of 49%, 53%, 64% and 69%. Two samples 
showed moderate inhibitions of 37% and 39%, while the rest were negative. 
The four positive sera from persons above 60 years, constituted 36% of the 
population studied. 
Cancer sera were similarly screened for the presence of antibodies 
reactive with native and ROS-DNA. Six out of eight sera from breast cancer 
patients were found to recognize nDNA and ROS-DNA, with five recognizing 
ROS-DNA to a greater extent than nDNA. One serum showed higher 
recognition of nDNA over ROS-DNA. One serum each from cancer of the 
lung, urinary bladder, prostate and renal cell also showed higher reactivity 
with ROS-DNA compared to nDNA. One serum each from caecum, lung and 
prostate cancers showed positive recognition of both ROS-DNA and nDNA. 
One serum from cancer of the urinary bladder showed a higher recognition of 
nDNA. Three out of four sera from hepatocellular cancer and two of five sera 
from carcinoma of the gall bladder showed high recognition of ROS-DNA. 
One serum was tested of Hodgkin's lymphoma and was found to recognize 
nDNA better (53%) over ROS-DNA (30%). Sera from cancer of rectum/ano-
rectal, ovarian, penis, stomach, bronchus, rhabdomyosarcoma showed no 
recognition of native and ROS-DNA. 
Oxida t ive damage to human genomic DNA was de t ec t ed 
immunochemically using the monoclonal anti-ROS-DNA antibody as a probe. 
Among the three DNA isolates from patients with breast cancer, two were 
observed to be recognized and bound by the monoclonal antibody, with 
maximum inhibitions of 58% and 40% in a competition ELISA. One DNA 
isolate of three from lung cancer was also inhibitory of monoclonal antibody 
activity with an inhibition of 53%. One sample each of hepatocellular and 
gall bladder carcinoma were also found to be reactive towards the antibody, 
showing maximum inhibitions of 46% and 42% respectively. DNA samples 
from prostate cancer were not inhibitory. 
The study points out physico-chemical alterations in DNA following 
modification by hydroxyl radicals, rendering the molecule immunogenic. 
Monoclonal antibodies generated against ROS-DNA showed some degree of 
cross-reactivity, nevertheless, the recognition was preferential for ROS-
modified epitopes on DNA, bases and polynucleotides rather than their 
native or unmodified forms. The study also showed a high prevalence of 
circulating antibodies in cancer sera and sera from individuals of different 
age groups, reacting preferentially with ROS-DNA over nDNA. The increase 
in levels of antibodies to DNA points out to the activation of autoreactive 
cells in cancer and aged individuals. Higher recognition of ROS-DNA 
indicates increased oxidative stress in both the groups resulting in DNA 
damage. The monoclonal antibody was demonstrated as a good probe to 
detect oxidative damage to the human genome. 
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Reactive oxygen species (ROS) are formed continuously in living cells 
as a consequence of normal metabolic and biochemical reactions as well as 
in pathological conditions. Although some ROS have important physiological 
functions, they nevertheless, have a wide potential for causing cell injury. 
The oxidative damage caused to DNA is an important factor in mutagenesis 
and carcinogenesis. Among the ROS, *0H radical is the most damaging and 
can virtually react with any macromolecule it encounters. In vivo, hydroxyl 
radicals are formed by ionizing radiations or through the Haber-Weiss or 
Fenton reactions. The hydroxyl radical, thus generated, causes DNA damage 
leading to strand breaks, base damage and conformational changes. 
Commercially available calf thymus DNA was purified free of proteins 
and single-stranded regions and digested with micrococcal nuclease to obtain 
fragments of about 70 - 800 bp. Aqueous solutions of native and 400 bp DNA 
were irradiated by UV light (254 nm) in the presence of hydrogen peroxide. 
Chemical alterations induced in DNA following modification by *0H, were 
studied by thermal denaturation, sedimentation in alkaline sucrose density 
g r a d i e n t , nuc lease SI d iges t ib i l i ty and h y d r o x y a p a t i t e column 
chromatography. Modified DNA samples showed a marked hypochromicity at 
260 nm over the unmodified DNA, reflecting the modification of bases in 
ROS-DNA. 
The Tm of native ROS-DNA was determined to be 81°C, while that of 
nDNA was found to be 87.5°C, showing a net decrease of 6.5°C. The Tm of 
400 bp-ROS-DNA was 73°C and that of its unmodified counterpart was 
87 .5°C . The genera t ion of single s trand breaks was r e i t e r a t ed by 
i i 
hydroxyapat i te column chromatography and nuclease SI digestibil i ty. 
Hydroxyl radical was found to induce DNA base modifications, which was 
quantified by ion exchange chromatography on DEAE Sephadex A-25. In the 
case of ROS-DNA, all the four bases were found to be modified. Thymine 
was modified the most (46,8%), followed by guanine (30.6%), cytosine 
(19.8%) and adenine (16.7%). In case of 400 bp ROS-DNA as well, the 
modification of thymine was maximum (58.3%). 
Native ROS-DNA was used to induce antibodies in goat. The ROS-
DNA was found to be a potent immunizing stimulus, inducing high titre 
antibodies. The antigenic specificity of the induced antibodies was studied 
by competition ELISA. The immunogen showed a high degree of specificity 
for the induced antibodies. In addition, the antibodies also showed a 
considerable recognition of native DNA. The results indicate the recognition, 
in part , of some antigenic determinant common to both ROS-modified and 
nDNA, which could be the sugar-phosphate backbone of the nucleic acids. 
Adenine, thymine and homopolymers poly(dA) and poly(dT) and their 
ROS-modified forms were also used as inhibitors in competition ELISA. It 
was observed that adenine, ROS-adenine and thymine showed negligible 
inhibition, while ROS-poly(dA) showed a high degree of inhibition. However, 
of special interest was the inhibition of 53% and 59% by ROS-thymine and 
ROS-poly(dT). The data clearly indicates the recognition of epitopes 
generated on thymine and poly(dT) after ROS-modification. The induced 
antibodies showed a broad spectrum of reactivity as indicated by their 
binding to synthetic polynucleotides. The antibodies showed inhibitions of 
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55%, 5 1% and 48.5% respectively with poly(dG).poly(dC) , poly(dA-
dC).poly(dG-dT) and poly(dG-dC).poly(dG-dC), while poly(dI-dC).poly(dI-
dC) and poly(rG).poly(dC) were non-inhibitory. The binding of the antibodies 
to ROS-DNA and nDNA was also ascertained by band shift assay. 
Monoclonal antibodies were generated against 400 bp ROS-DNA. A 
high binding monoclonal (PjCjjD^) was chosen for this study. The monoclonal 
antibody showed a high inhibition in its activity, to the extent of 84% when 
ROS-DNA was used as inhibitor and a lower inhibition of 60% with 200 bp 
ROS-DNA. The antibody also showed cross-reactivity with nDNA, showing 
an inhibition of 65%. 
The fine antigenic specificity of the monoclonal antibodies was studied 
by competition ELISA, using nitrogenous bases, homopolynucleotides and 
their ROS-modified forms as competitors.. Thymine, thymidine, adenine, 
ROS-adenine, cytosine, ROS-cytosine and guanine showed negligible 
inhibition. In contrast, ROS-thymine, ROS-thymidine and ROS-guanine 
showed high inhibitions of 66.5%, 57% and 48% respectively. Poly(dA), 
ROS-poly(dA), poly(G) and poly(dT) were non-inhibitory of monoclonal 
antibody binding to ROS-DNA. However, ROS-poly(dT) was observed to be 
an effective inhibitor showing a maximum inhibition of 68%, while inhibition 
by ROS-poly(G) was 47%. 
The reactivity or recognition of native and ROS-DNA by antibodies in 
the sera of healthy, normal humans of different age groups was studied by 
competition ELISA. Sera from the control or the young age population 
showed negligible reactivity towards the two polymers. In contrast, three 
I V 
sera from individuals in the age group 50-59 years showed a high binding 
to ROS-DNA with maximum inhibitions of 43-47%, while one serum showed 
greater reactivity with nDNA. Similarly, sera from the age group over 60 
years showed greater reactivity for ROS-DNA. Four sera showed high 
inhibitions of >60% with ROS-DNA as inhibitor, while the inhibition was in 
the range of 55-60% with nDNA. One serum showed a moderate binding to 
ROS-DNA, while one recognized nDNA better than ROS-DNA. The data 
indicates a definite increase in the levels of antibodies reacting with ROS-
DNA and nDNA, with a higher recognition of oxidatively damaged DNA with 
advancing age. 
Monoclonal anti-ROS-DNA antibody was used as a molecular probe to 
detect oxidative DNA damage in normal healthy individuals. DNA was isolated 
from lymphocytes of normal human subjects of varying age groups. The 
isolated DNA was used as inhibitor in a competition ELISA. The results 
indicate a low recognition of DNA from young age groups (<35 and 35-49 
years) by the monoclonal antibody. In the age group 50-59 years, one DNA 
isolate showed a high inhibition (57%) of monoclonal antibody binding to 
solid-phase antigen, while four more samples showed lower inhibitions of 
40-42% and three samples were negative. In the age group above 60 years, 
four DNA samples were recognized to a great extent by the monoclonal 
antibody, giving an inhibition of 49%, 53%, 64% and 69%. Two samples 
showed moderate inhibitions of 37% and 39%, while the rest were negative. 
The four positive sera from persons above 60 years, constituted 36% of the 
population studied. 
Cancer sera were similarly screened for the presence of antibodies 
reactive with native and ROS-DNA. Six out of eight sera from breast cancer 
patients were found to recognize nDNA and ROS-DNA, with five recognizing 
ROS-DNA to a greater extent than nDNA. One serum showed higher 
recognition of nDNA over ROS-DNA. One serum each from cancer of the 
lung, urinary bladder, prostate and renal cell also showed higher reactivity 
with ROS-DNA compared to nDNA. One serum each from caecum, lung and 
prostate cancers showed positive recognition of both ROS-DNA and nDNA. 
One serum from cancer of the urinary bladder showed a higher recognition of 
nDNA. Three out of four sera from hepatocellular cancer and two of five sera 
from carcinoma of the gall bladder showed high recognition of ROS-DNA. 
One serum was tested of Hodgkin's lymphoma and was found to recognize 
nDNA better (53%) over ROS-DNA (30%). Sera from cancer of rectum/ano-
rectal, ovarian, penis, stomach, bronchus, rhabdomyosarcoma showed no 
recognition of native and ROS-DNA. 
Oxidat ive damage to human genomic DNA was de t ec t ed 
immunochemically using the monoclonal anti-ROS-DNA antibody as a probe. 
Among the three DNA isolates from patients with breast cancer, two were 
observed to be recognized and bound by the monoclonal antibody, with 
maximum inhibitions of 58% and 40% in a competition ELISA. One DNA 
isolate of three from lung cancer was also inhibitory of monoclonal antibody 
activity with an inhibition of 53%. One sample each of hepatocellular and 
gall bladder carcinoma were also found to be reactive towards the antibody, 
showing maximum inhibitions of 46% and 42% respectively. DNA samples 
from prostate cancer were not inhibitory. 
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The study points out physico-chemical alterations in DNA following 
modification by hydroxyl radicals, rendering the molecule immunogenic. 
Monoclonal antibodies generated against ROS-DNA showed some degree of 
cross-reactivity, nevertheless, the recognition was preferential for ROS-
modified epitopes on DNA, bases and polynucleotides rather than their 
native or unmodified forms. The study also showed a high prevalence of 
circulating antibodies in cancer sera and sera from individuals of different 
age groups, reacting preferentially with ROS-DNA over nDNA. The increase 
in levels of antibodies to DNA points out to the activation of autoreactive 
cells in cancer and aged individuals. Higher recognition of ROS-DNA 
indicates increased oxidative stress in both the groups resulting in DNA 
damage. The monoclonal antibody was demonstrated as a good probe to 
detect oxidative damage to the human genome. 
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In 1953, James Watson and Francis Crick first enunciated the double helical 
structure of DNA with the axis of the helix running through the Watson-Crick base 
pairs. This model of DNA known as B-DNA is the most widely accepted structure 
of DNA in solution. However, DNA can adopt many more different conformations 
or structures (Rich ., 1984). X-ray diffraction studies have thrown light on the 
alternative conformations such as A- and C-DNA within the right handed family 
(Adams et al., 1981). These differences in molecular form are of crucial importance 
in understanding the manner in which proteins interact and recognize nucleotide 
sequences in B-DNA as compared to A-DNA. Wang et al. (1979) described a 
variant of B-DNA double helix in a DNA hexamer with a sequence d(CGCGCG). 
The two strands of the duplex were anti-parallel and connected by Watson-Crick 
base pairs, but the helix was left handed. The backbone had a zig-zag shape and was 
termed Z-DNA. The Z-conformation is adopted by flipping of the base pairs upside 
down. Synthetic polynucleotides have been described to form triple-stranded 
nucleic acids spontaneously (Felsenfeld et al., 1957). Triple-stranded nucleic acids 
have since been found to exist in DNA using a variety of hydrogen bonding 
arrangements in the major groove of B-DNA. A typical example is the formation of 
triple-stranded DNA as an intermediate in the action of E. coli recombination 
enzyme RecA (Camerini-Otero and Hseih, 1993). Another unique structure is the 
quadruple-stranded nucleic acids (Rich, 1958). The X-ray diffraction pattern of 
polyinosinic acid and polyguanylic acid indicated that the polynucleotide strands 
were parallel to each other with a three or four fold symmetry axis along the fibre 
(Rich, 1958; Zimmerman et al., 1975). Other conformations include the cruciform 
structure form, widely found in the eukaryotic genome (Wilson and Thomas, 1974; 
Lu et al., 1992). These are formed by inverted repeat sequences or palindromic 
sequences which form complementary base pairs and may serve as in vivo signals. 
The different conformations adopted by DNA reflects its enormous versatility that 
is inherent in the molecule. 
Antigenicity of DNA 
The antigenic property of nucleic acids was recognized much later than those 
of proteins and polysaccharides. Early reports indicated the presence of anti-DNA 
antibodies in patients with systemic lupus erythematosus (SLE) and identified DNA 
as the reactant for these autoantibodies (Cepellini ., 1957; Robbins et al., 1957; 
Seligmann, 1957). The evidence that DNA served as the antigen was established by 
using highly purified DNA, RNA not reacting to the autoantibodies, the loss of 
reactivity after digestion with deoxyribonuclease (DNase) but not with ribonuclease 
(RNase) or proteolytic enzymes. In the early 1960's,methods were developed for 
the experimental induction of antibodies to nucleic acids (Levine et al., 1960; 
Erlanger and Beiser, 1964; Plescia et al., 1964). 
The notion that DNA is immunologically inactive derives primarily from 
efforts to replicate SLE by immunization of normal animals with DNA. When 
presented with a protein carrier methylated BSA (MESA) and administered in 
adjuvant, mammalian DNA elicits poor responses to single-stranded (ss) DNA and 
fails to induce antibodies against native or dsDNA (Madaio et al., 1984), the 
serologic hallmark of SLE. Recent studies have, however, shown that DNA 
complexes with a synthetic peptide Fus-1 can induce an anti-dsDNA response in 
mice (Desai etal., 1993). Anti-DNA antibodies may also result by autoimmunization 
with chromatin, rather than native DNA (nDNA) (Theofilopoulos, 1995). 
Nevertheless, these experiments demonstrated that the antigen drive in lupus 
involves either a substance other than DNA or DNA in a form that is not readily 
mimicked by artificial complexes (Burlingame et al., 1993; Mohan et al., 1993). 
Immunization of experimental animals with synthetic nucleic acid polymers like 
poly(dT), poly(dC), poly(dA), poly(dl), poly(G), left-handed Z-DNA and double 
stranded DNA with the notable exception of native B-DNA can induce antibodies 
that react selectively with the immunogen (Stollar, 1986). 
The DNA molecule has several unique features which have a direct bearing 
on its immune reactions. First, it exists in nature in two different basic conformations 
- a double-stranded (right-handed double helix) and single-stranded conformation, 
apart from a left-handed DNA or Z-DNA (Wang et al., 1979). A second feature of 
DNA is its multideterminant nature. DNA is an acidic polymer with repeating units 
both in terms of the nucleotides and the regular turns of the helix. The third feature 
is its polyanionic nature, the helical polymer having a hydrophobic core of stacked 
bases and a sugar phosphate backbone with highly acidic phosphate residues. 
While native B-DNA is non-immunogenic, the left-handed Z-DNA is a 
potent immunogen (Lafer et al., 1981;Madaio et al., 1984) inducing antibodies that 
are selective and specific and do not react with nDNA or ssDNA (Zarling et al., 
1984). Chemically or physically modified DNA or helical structures that differ 
significantly from B-DNA are much stronger immunologic stimuli than nDNA and 
most of the antibodies induced by modified nDNA do not react with the unmodified 
DNA (Anderson et al., 1988a). Calf thymus DNA modified with drugs, hormones, 
free radicals etc. has been reported to induce antibodies against the modified 
polymer (Moinuddin and Ali, 1994; Ara and Ali, 1995; Arjumand et al., 1995). 
Several polynucleotides which differ in conformation from the B-DNA helical 
conformation are much stronger immunogens than native B-DNA (Braun and Lee, 
1988). Polynucleotides of B-conformation become immunogenic after modification 
with furocoumarins (Arif and Ali, 1996). 
In contrast to mammalian DNA, bacterial DNA can induce a variety of 
responses in both normal humans as well as animals. A surprising finding was the 
recognition of bacterial DNA from two species Micrococcus lysodeikticus and 
Staphylococcus epidermidis by normal human sera (Karounos et al., 1988). This 
finding was in contrast to the normal dogma that anti-DNA antibodies are prevalent 
in lupus alone. These antibodies were highly specific and did not react with other 
DNA. Fredriksen et al. (1993) reported the recognition of DNA from BK polyoma 
virus by normal human sera. Studies have also demonstrated that complexes of 
bacterial DNA and MBSA are immunogenic in normal mice (Gilkeson et al., 1989). 
However, the induced antibodies binds poorly if at all to mammalian DNA. Anti-
DNA antibodies are also induced with BK virus that binds to viral DNA but is still 
different from autoimmune anti-DNA antibody (Flaegstad et al., 1988; Fredriksen 
etal., 1991). 
A plausible explanation for the occurrence of anti-DNA antibodies is their 
generation during infection to sequence regions in host DNA. The immune response 
to foreign DNA is analogous to that of foreign proteins in that, it does not require 
T-cell recognition. The antibodies are of IgG2 isotype, quite distinct from SLE 
autoantibodies which are predominantly IgGl and IgG3. This type of isotype 
expression suggests that the responses to foreign DNA are distinct from the lupus 
anti-DNA response which appears to be T-cell dependent (Robertson et al., 1992). 
In contrast to normal mice, autoimmune mice (NZB/NZW), immunized with 
bacterial or viral DNA, produce cross-reactive antibodies to mammalian DNA 
(Fredriksen et al., 1994; Gilkeson et al., 1995). The antigenic specificities of these 
induced antibodies are comparable to the SLE anti-DNA autoantibodies. The 
responsiveness of the autoimmune mice to DNA reflects defects in tolerance and 
allows retention of autoreactive clones that can bind dsDNA (Gilkeson et al., 
1993). This would indicate that foreign DNA can drive the production of anti-DNA 
autoantibodies in a host susceptible to SLE. Evidence for this possibility is the 
presence of bacterial DNA in immune complexes of SLE sera (Terada et al., 1991). 
These and other studies on DNA immunogenicity and the occurrence of anti-DNA 
antibodies have been elegantly and comprehensively reviewed (Zouali et al., 
1988; Stollar, 1989; Tan, 1989; Pisetsky et al., 1990; Stollar, 1992; 1994; Pisetsky, 
1996). 
Monoclonal antibodies to DNA have allowed precise delineation of antibody 
specificity. They have provided valuable insights into the interactions of antibodies 
with DNA and the possible mechanisms stimulating the anti-DNA antibody responses 
(Emlen et al., 1986). Anti-DNA antibodies are polyspecific and bind to many 
heterogenous molecules (Andrzejewskie/Of/., 1981; Shoenfeld etal., 1983; Isenberg 
et al., 1994). Monoclonal antibodies differ markedly in their reactivity with 
polynucleotides of different base composition, suggesting that they bind or recognize 
sequence specific determinants on DNA. Some monoclonal antibodies, however, 
show polyspecificity reacting with phospholipids, proteoglycans, bacterial antigens 
and cell surface antigens (Shoenfeld et al., 1983; Jacob et al., 1984; Caroll et al., 
1985). 
Free Radicals 
The reduction of oxygen generates reactive intermediates or free radicals 
(Fridovich, 1978; Thornalley and Bannister, 1985). A free radical is any atom or 
molecule containing one or more unpaired electrons (Halliwell and Gutteridge, 
1989). The unpaired electrons drastically alter the chemical reactivity of the 
molecule, usually making it more reactive than the corresponding non-radical form 
(Halliwell, 1994). The usual route for metabolism of molecular oxygen involves its 
complete reduction to H^O by accepting four electrons (Yu, 1994). However, with 
one electron reduction, several free radicals and H^O^ can be formed as shown 
below: 
Oj + e~ > 0*~ (superoxide radical) 
Oj + HjO > HO'^+OH- (hydroperoxyl radical) 
HO'j + e" + H > H^O^ (hydrogen peroxide) 
H^O^ + e- > 'OH + OH- (hydroxyl radical) 
The reactive oxygen species (ROS) are highly reactive and have extremely 
short half-lives (Table 1). This reactivity is due to the unstable electronic 
configuration of the radicals. They readily extract electrons from other molecules 
with which they collide and this in turn becomes a free radical and thus highly 
reactive, perpetuating a chain reaction. 
Free radicals are generated in vivo by oxidant enzymes, phagocytic cells, 
redox-cycling drugs, ionizing radiations etc. (Halliwell and Gutteridge, 1989). 
These radicals cause damage to a number of macromolecules including lipids and 
proteins (Lunec et al., 1985; Wolff er al., 1986; Lunec, 1990). However, the most 
susceptible is DNA (Ballmer et al., 1994; Runger et al., 1995) thus modulating 
mutagenesis and /or carcinogenesis (Brawn and Fridovich, 1985; Breimer, 1990; 
Breen and Murphy, 1995). Apart from their role in antimicrobial defense mechanism, 
TABLE 1 
Some Characteristics and Half Lives of free radicals* 
Species 
Superoxide 
anion 
Hydroxyl 
radical 
Chemical 
symbol 
o'r 
'OH 
Half life at 
37°C (sec) 
1 X 10-« 
1 X 1 0 ' 
Properties 
Good reductant, poor oxidant 
Extremely reactiVe (addition, 
abstraction, and electron 
transfer reactions), very low 
difiusion distance 
Peroxyl 
radical 
Alkoxyl 
radical 
ROO 
RO* 
1 X 10>^  
1 X 10-*-
Low oxidizing ability relative 
to 'OH, but great dififlisibility 
Intermediate in their reactivity 
with lipid between ROO* 
and *0H 
Singlet 
oxygen 
'O. 1 X 10-* Powerful oxidizing agent 
Molecular 
oxygen** 
O, >10^ 
'Adapted from Florence, T.M. (1990) Proc. Nutr. Soc. Aust. Annu. Conf 15, 88-93. 
Ross, D. and Moldeus, P. (1991)In: Membrane Lipid Peroxidation, Vigo-Pelfrey C. (Ed.), 
pp. 151-170. CRC Press, Boca Raton, Florida. 
"Molecular oxygen was taken for comparison 
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reactive oxygen species are involved in important processes related to signal 
transduction and gene expression (Los et al., 1995). The major biological processes 
leading to the generation of 0'~ is the electron transport chain (Halliwell and 
Gutteridge, 1986; Halliwell, 1989). Within the mitochondria, the steady-state 
concentration of 0'~ is estimated to be 8 x 10"'^  (Freeman, 1984). Most of the 0'~ 
generated is, however, converted to H^O^ by superoxide dismutase. Respiratory 
bursts during phagocytic activity generate ROS, so essential for the host defense 
against invading microbes or infectious agents. Substantial amounts of H^O^ is 
produced and this is primarily responsible for the cytotoxic potential seen in 
localized tissue inflammation (Heffiier and Repine, 1989). In addition, hydroxyl 
radical (OH) may also be generated during phagocytosis either by the Haber-Weiss 
reaction or the iron-catalyzing Fenton reaction. 
Among the ROS, superoxide anion radical is the first intermediate in the 
sequential univalent reduction of O^ leading to the formation of H^O (Florence, 
1990; Harris, 1992). The anion radical is unique, since it can lead to the formation 
of many other reactive species like *0H, H^O^ and perhydroxyl (HO'^ ) radicals 
(Pryor, 1984). Superoxide radical interacts with H^O^ to generate the singlet 
oxygen molecule, another reactive oxygen species. The most important feature of 
Or is its ability to act as a Bronsted base, by which, in aqueous media, the acid-base 
equilibrium (pKa=4.8) is shifted to form a hydroperoxyl radical. In an acidic 
environment, then, 0*^  readily generates HjO^. At neutral or higher pH, the 
dismutation of 0'~ is catalyzed by superoxide dismutase (Gregory et al., 1973; 
Fridovich, 1975). Although, H^O^ by definition is not considered an oxygen free 
radical, it nevertheless remains the most extensively studied oxygen metabolite 
(Harris, 1992). It is a secondary product of one-electron oxidation* 
O; + O- + 2H^ > H,0, + O, 
The dismutation of 0'~ by superoxide dismutase is a major source of H^O .^ By 
itself, HjOj is not reactive enough to oxidize many organic molecules. However, 
reports exist of DNA damage by H^O^ (Burdon et al., 1996). Nevertheless, it is a 
biologically important oxidant, given its ability to generate highly reactive hydroxyl 
radicals by interaction with redox-active transition metals (Aruoma and Halliwell, 
1987; Aruoma et al., 1991). The importance of H^O^ is therefore placed on the 
initiation of free radical cytotoxicity rather than its chemical reactivity. 
In sharp contrast, the'OH is potentially the most potent oxidant encountered 
in biological systems. Because of its extremely short half-life (Table 1 ), its 
diffusion capacity is restricted to only about two molecular diameters before 
reacting (Fee and Valentine, 1977). The *0H readily reacts with a variety of 
biological macromolecules including DNA, protein, membrane lipids and cause 
DNA-protein crosslinks (von Sonntag, 1987a,b; Dizdaroglu, 1991; Halliwell and 
Aruoma, 1991). The biological importance of OH as oxidants was first suggested 
during generation by X-ray irradiation. Cellular generation of OH may occur by 
several routes (Aruoma and Halliwell, 1987; Aruoma et al., 1991), although two 
common and important biological sources deserve special mention. The first is their 
generation by the decomposition of H^O^ via the Fenton reaction (Fenton,1894) 
Fe^* + H^O^ > Fe^^ + *0H + OH" 
and the second, by the interaction of superoxide with H^O^ through the Haber-
Weiss reaction (Haber and Weiss, 1934). 
to 
O- + H^O^ > Oj + H^O + OH 
Hydroxy! radicals can also be generated when the reduced forms of transition 
metal ions such as copper or chromium (Shi ei al., 1994) combine with H^O^ 
Cu^ + H^O^ > Cu'^ + OH + OH-
lonization radiation reacts with water molecules to give a hydrated electron (e' ) 
and H^O, which rapidly loses a proton to give the OH (von Sonntag, 1987c). 
hv 
H O > H O ' " + e-
2 2 >q 
very fast 
HJO" + HJO > H3O" + O H 
Cellular Damage by Free Radicals 
The primary or the most susceptible target of free radicals in vivo is DNA. 
Apart from the free radicals, DNA is also inflicted by radiation and chemicals 
(Simic and Jovanovic, 1986). Radiation chemistry has primarily helped in the 
understanding of free radical mediated DNA damage (Scholes, 1983). Ionizing 
radiations, chiefly y-radiation are primarily responsible for DNA damage (Teoule, 
1987; von Sonntag, 1987a,b,c,; Kuwabara, 1991) causing cell death, mutagenesis 
and carcinogenesis. Ionizing radiations may be absorbed directly by DNA, leading 
to ionization of bases (Steenken, 1989), strand-breaks and formation of thiobarbituric 
acid reactive material (Hems, 1960; Kapp and Smith, 1970). 
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Hydrogen peroxide in the presence of ferrous or copper ions, generates'OH 
through Fenton or Fenton-like reactions. The radical is also generated by exposure 
to ultraviolet light. The ROS generated by these methods damage and cleave DNA 
(von Sonntag, 1987d; Goldstein e/a/., 1993). The *0H is a highly reactive radical 
causing extensive damage to biological macromolecules and deleterious reactions 
in vivo (Imlay and Linn, 1988; Shi, 1994a,b). Oxidative damage to DNA induces 
strand breaks (Dizdaroglu, 1993), sister chromatid exchanges and subsequent 
production of clastogenic factors (Emerit et al., 1985), alterations in base structure 
(Olinski et al., 1992) and conformational changes (Allan et al., 1988). It is reported 
that oxidative DNA damage relates positively with oxygen consumption in humans 
(Loft et al., 1994). In general, the nitrogenous bases react preferentially with'OH 
over the sugar moiety by 4-6 fold and each of the bases forms a series of modified 
derivatives (Hutchinson, 1985, Deeble et al., 1986, von Sonntag and Schuchmann, 
1991). Among the five major components of DNA, thymine and cytosine are most 
susceptible to OH damage, followed by adenine, guanine and deoxyribose (Saul et 
al., 1987). 
A major family of thymine oxidation products are the thymine glycols -
consisting of four isomers of 5,6-dihydroxy-5,6-dihydrothymine, in which the 
vicinal hydroxyl groups are either cis- or trans- to each other (von Sonntag, 
1987a-d; Dizdaroglu, 1992). Under most conditions, the cis-glycol predominates 
and the R-configuration (of the 5-carbon) is the main product in native DNA 
exposed to y-radiation or chemical oxidants (Dizdaroglu, 1992). Release of intact 
thymine glycol from DNA can be assayed by HPLC (Demple and Linn, 1980) and 
in urine as an indicator of endogenous DNA damage (Cathcart et al., 1984). Most 
oxidation products of cytosine are analogous to those detected for thymine. The 5,6-
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hydrated cytosines in DNA even predominate over thymine glycols after H O 
2 2 
treatment of cultured mammalian cells (Dizdaroglu, 1992). Cytosine glycols so 
formed, can undergo deamination to form uracil derivatives, which basepair 
preferentially with adenine instead of guanine. This process probably enhances the 
mutagenic effects of cytosine hydrates relative to thymine glycols. 
Hydroxy! radicals have been shown to add to C-4,5 and 8 of guanine to give 
G40H, G50H and G80H radicals. In this case, the 'OH adducts exhibit redox 
ambivalence, i.e. they can be both oxidizing and reducing (Steenken, 1989). 
Reduction leads to ring opening forming formamidopyrimidine (FAPy) derivative. 
FAPyG has been shown to form in DNA (Fuciarelli et al., 1990), chromatin 
(Gajewski ei al., 1990), in human cells (Nackerdien et al., 1992). Alternatively, 
oxidation of C-4 and C-2 forms G80H and loss of a proton rearomatizes the 
imidazole ring to give 8-hydroxyguanine (8-oxo-dG) (Steenken, 1989). This 
derivative has been isolated from irradiated DNA (Dizdaroglu, 1985; Fuciarelli et 
al., 1990; Rosen g^  a/., 1996), chromatin (Gajewski e/a/., 1990), human cells (Kasai 
et al., 1986; Nackerdien et al., 1992). The 8-hydroxyguauine is one of the most 
abundant base lesions formed by UV (Floyd et al., 1988) and ionizing radiations 
(Kasai et al., 1986; Pllaum et al., 1994 ) and is highly mutagenic (Cheng et al., 
1992; Moriya, 1993). It is used as a specific marker of oxidative damage to DNA 
and allows for the study into possible DNA reactions in vivo (Kasai et al., 1986). 
Oxidatively damaged DNA was found to contain 8 to 83 of these residues/lO*" 
deoxyguanosine. It is also found to be increased with age in liver, kidney and 
intestine but not in brain or testes (Fraga etal., 1990; Floyd 1993) in rats. Sensitive 
methods such as HPLC and GC-MS have been described to measure 8-oxo-dG 
(Cundy et al., 1988; Lunec et al., 1994) 
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A highly accessible moiety to'OH, is the phosphodiester backbone of DNA. 
The polyanion readily attracts metals such as Fe^^ or Cu* and targets the localized 
formation of OH by H^O^ (Imlay and Linn, 1988). The damage caused can displace 
bases, oxidize deoxyribose and fragment the sugar (Demple and Harrison, 1994). 
Radical attack at C, can eliminate the apparently undamaged base and oxidize C^ 
to the carboxylate to form deoxyribonic acid (Dizdaroglu et al., 1977). Base 
displacement can also occur after the attack at C^ which can form 4-keto-
deoxyribonate (Dizdaroglu et al., 1977). Both these lesions leave DNA intact, but 
the lability of these abasic sites in alkali allows their release from oxidized DNA 
(Dizdaroglu et al., 1977; Beesk et al., 1979). Removal of damaged bases by repair 
enzymes called DNA N-glycosylases is also observed. These are the apurinic or 
apyrimidinic (AP) sugars or the AP sites and may be mutagenic within the DNA 
chain (Loeb and Preston, 1986). DNA containing the AP sites preferentially insert 
adenine opposite the lesions (Kunkel et al., 1983) leading to mutations wherever 
the lost base was other than a thymine. AP sites can inhibit DNA synthesis (Sagher 
and Strauss , 1983). Sugar damage leading to strand scission such as 3 ' -
phosphoglycolate ends or 3'-phosphate ends to DNA chain cannot be acted upon by 
DNA polymerases either as a template or as a primer (Henner et al., 1983), in 
particular double-stranded breaks which lead to cell death in vivo. 
DNA-protein crosslinks are generated by ionizing radiations (eg. thymine 5-
methyl to tyrosine 4-oxygen) (Oleinick et al., 1986). Small amounts of interstrand 
crosslinks may be formed by radical attack. The crosslinks formed within the same 
chain could be cytotoxic or mutagenic, as in the case of cis-platinum or UV-induced 
pyrimidine dimers (Sancar and Sancar, 1988) 
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Repair of Oxidative Damage to DNA Bases 
Free radical damage to DNA constitutes a constant and significant threat to 
aerobic organisms. Enzymes that attack specific oxidative damages are widespread 
among oxygen-using bacteria and yeast and mammalian cells. Although free radical 
attack produces a multitude of DNA damages, the ability of atleast some of these 
repair activities to recognize a range of substrates allows relatively few enzymes 
to repair the bulk of base and sugar lesions. General repair mechanisms act as 
secondary repair pathways and can handle more complex lesions (Tainer et al., 
1995). 
(a) DNA glycosylases 
DNA glycosylases initiate DNA repair. These enzymes excise bases and 
subsequently, phosphodiester bonds on each side of the abasic site which are incised by 
endonucleases, allowing insertion of an intact nucleotide. Enzymes such as endonuclease 
III has both glycosylase and endonuclease activities for repair of oxidized pyrimidines. 
The formamidopyrimidine-DNA glycosylase (Fpg; mutM) of £. coli repairs 8-oxo-dG and 
2,6-diamino-4-hydroxy-5-formamidopyrimidine and to a lesser extent the corresponding 
adenine derivatives by base excision (Biotcux eta I., 1992). After liberation of the damaged 
base, exonucleases incise the apurinic site for insertion of a new nucleotide. In humans, 
similar two step pathways yielding 8-oxo-dG have been identified, in addition to repair of 
8-oxo-dG by single step excision of the complete nucleotide (Bessho et al., 1993). 
Oxidized nucleosides and nucleotides fi^om the cellular pools may be incorporated into 
DNA and lead to AT to GC base substitution mutations in case of 8-oxo-GTP (Kamiya et 
al., 1992; Shibutani et al., 1991). However, the mutT enzyme cleaves the phosphates of 
8-oxo-GTP with high aflBnity (Mo et al., 1992). A human homologue to this enzyme has 
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also been described (Furuichi et al., 1994). In E. coli, the mutM and mutT enzymes 
cooperate functionally with mutY, an enzyme which removes adenine misinserted opposite 
8-oxo-dG in DNA (Tajiri et al., 1995). 
(b) Repair of Deoxyribose Damage 
Exonuclease 111 is a major AP endonuclease of E. coli (Gossard and Verly, 
1978). It is also reported to have ribonucleaseH activity (Rogers and Weiss, 1980). 
Exonuclease III shows near absolute preference for double-stranded substrates. 
The 3'-phosphatase activity is highly specific for DNA (Rogers and Weiss, 1980). 
The 3'—>5' exonuclease degrades linear DNA from both 3'-ends (Richardson et al., 
1964) and also digests internal nicks (Richardson et al., 1964; Rogers and Weiss, 
1980). The AP endonuclease activity results in hydrolytic cleavage on the 5'-side 
of base-free deoxyribose (Rogers and Weiss, 1980), which leaves an abasic 5'-
terminal deoxyribose-5-phosphate. The 3'-termini generated by exonuclease III 
activity results in normal nucleotides with 3'-hydroxyl groups that are primers for 
DNA polymerases (Rogers and Weiss, 1980; Demple et al., 1986). 
(c) General Repair of DNA 
(i) Excision repair 
General repair systems that recognize diverse DNA lesions also act on 
oxidative damages. The nucleotide excision repair system oiE. coli is based on the 
UvrA, UvrB and UvrC proteins. These act in a complex series of reactions to locate 
and form incisions on both sides of DNA lesions (Grossman and Thiagalingam, 
1993; Sancar and Tang, 1993). DNA helicase, polymerase and ligase reactions then 
eliminate the 12- or 13- mer oligonucleotide and complete the repair. The UvrABC 
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system is essentially to repair the structural distorting lesions such as pyrimidine 
photodimers, some carcinogen adducts, cis-platinum intrastrand crosslinks 
(Grossman and Thiagalingam, 1993; Sancar and Tang, 1993). Nevertheless, in vivo 
and in vitro studies show a function for UvrABC as a secondary defense against 
oxidative damage (Sancar and Tang, 1993). In humans, DNA damages account for 
much of the cellular and genetic deterioration in individuals with xeroderma 
pigmentosum (Friedberg, 1985). The human excision repair system acts in vitro on 
DNA damage produced by y-rays or H^Oj/Cu^* , at lesions distinct from those 
recognized by endonuclease III and Fpg/MutM protein (Satoh et al., 1993). These 
damages could be dihydrothymine crosslinks (Dizdaroglu, 1992), 8,5'-
cyclodeoxyadenosines (Raleigh et al., 1987) and purine-purine intrastrand crosslinks 
(Carmichael et al., 1992). 
(ii) Re combinational repair 
Recombination mechanism can repair any DNA lesion, provided an intact 
copy of the affected region resides in the same cell (West, 1992). Oxidative 
damages include atleast two classes for which recombination would be crucial -
interstrand crosslinks and double-strand breaks. The former are substrates for the 
recombinational repair system of £. coli (Sancar and Sancar, 1988; West, 1992). 
Theories of Aging 
Aging is the accumulation of changes responsible for the sequential alterations 
that accompany advancing age and the associated progressive increases in the 
chance of disease and death. These changes may be attributed to disease, 
environment, immune dysfunction (Walford, 1980) and to an inborn process - the 
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aging process. This produces aging changes at an apparently unalterable, 
exponentially increasing rate with advancing age. The contribution of the aging 
process to aging changes are small early in life, but rapidly increase with age due 
to the exponential nature of the process (Harman, 1991). Many theories have been 
propounded to account for the aging process (Rockstein et al., 1974; Warner et al., 
1987; Medvedev, 1990), but no single theory is generally accepted. Infact, it is 
doubtful that a single theory will explain all the mechanisms of aging (Schneider, 
1987; Vijg, 1990a). 
Among the many theories advanced, the free radical theory of aging shows 
promise of application today. This theory was first proposed in 1954 by Harman 
(1955; 1956). This theory arose from a premise that a single common process, 
modifiable by genetics and environmental factors, was responsible for the aging 
and death of all living beings (Harman, 1981). It postulates that aging is caused by 
free radical reactions, i.e., these reactions may be involved in production of the 
aging changes associated with the environment, disease and the intrinsic aging 
process. This theory is based on the chemical nature of free radical reactions and 
their ubiquitous and prominent presence in living beings (Holmes et al., 1992; 
Greenstock, 1993; Nuhl, 1993). 
(a) DNA Damage and Aging 
An attractive explanation of the causes of aging is the damage to biosystems 
by free radical processes (Harman, 1991). It was postulated that, if free radical 
reactions were the major cause of aging, a reduction in their levels by anti-oxidants 
or antioxienzymes (eg. catalase,superoxide dismutase and glutathione peroxidase) 
should, in principle, retard aging with a concomitant increase in maximum life span. 
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However, levels of antioxidants and antioxienzymes in different mammalian species 
appear to be constant. This relationship has been explained by considering the 
concentrations of antioxidants and antioxienzymes relative to specific metabolic 
rate rather than absolute concentrations (Cutler, 1985a). It is now possible to 
measure less than nM levels of products generated by oxidative damage to DNA 
(Dizdaroglu, 1991), with the measurements made either directly on DNA or on 
excised damage products found in urine (Ames, 1989a; Shigenaga and Ames, 
1991). The yield of urinary biomarkers of oxidative DNA damage is related to 
specific metabolic rate (Ames, 1989a) more justifiably to maximum life span (Simic 
and Bergtold, 1991a). 
McCay et al. (1943) first reported an important relationship between life 
span and dietary caloric intake in rats and mice. They observed that animals fed 
calorically restricted diets lived about one-third longer than animals fed ad libitum. 
A new hypothesis to account for the molecular mechanisms of caloric restriction 
effects was based on the rate of DNA damage (Simic and Bergtold, 1991a,b) and 
was extended further to the mechanisms of aging. It was proposed that a high 
metabolic rate as a result of unrestricted caloric intake should generate higher yields 
of Oj, H^O^ and'OH (Szatrowski and Nathan, 1991). 
The *0H react rapidly with deoxyribose and DNA bases (von Sonntag, 
1987a). Two products of OH damage to DNA serve as suitable DNA biomarkers -
thymine glycol and 8-hydroxyguanine. These modified bases are eliminated by 
DNA repair enzymes. An equilibrium level of these products on DNA, however, 
is always present (Fraga et al., 1990). Formation, measurement and application of 
these products to aging and carcinogenesis have been reviewed (Simic, 1992). 
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Species with a high metabolic rate also have a high rate of oxidative DNA 
damage (Ames, 1989a), with humans having the lowest rate of DNA damage. The 
studies showed that the yields of biomarkers were not proportional to specific 
metabolic rate, indicating the participation of other parameters like the efficacy of 
the antioxidant defense system. Dietary caloric intake was found to play a major 
role in the rate of oxidative DNA damage (Simic and Bergtold, 1991a,b). The effect 
of caloric intake on DNA damage is, however, not as large as compared to the 
effect of specific metabolic rate of different species. For mice and rats, a 40% 
reduction in dietary caloric intake extended maximum life span by one-third 
(Weindruch and Walford, 1988). Dietary caloric intake may also affect the fidelity 
of DNA repair (Turturro and Hart, 1991) and general free radical damage observed 
in organisms (Yu, 1994). Therefore, a reduced rate of oxidative DNA damage, 
increased fidelity of DNA repair and an overall decrease in free radical damage 
constitute a molecular basis for extension of maximum life span in organisms 
subjected to caloric restriction (Haley-Zitlin and Richardson, 1993). 
Cancer and aging, the two biological consequences with the most complex 
etiology, also may be a function of other types of endogenous DNA damage. 
Despite enzymatic repair and other defences, continuous DNA damage progressively 
alters genomic sequence (Moraes et al., 1990; Shibutani et al., 1991), as indicated 
by aging (Vijg, 1990b; King et al., 1994) to the development of cancer by activation 
of oncogenes or inactivation of suppressor genes. Consequently, the probability of 
mutation and concomitant development of tumors and reduction of maximum life 
span increases with the rate of oxidative DNA damage. 
The apparent relationship between DNA damage and maximum life span 
warrants two major conclusions: 
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(i) Agents or processes that increase the rate of DNA damage and diminish 
DNA repair may accelerate the rate of aging and decrease life span (Weirich-
Schwaiger et al., 1994). 
(ii) The rate of damage apparently may be decreased by lowering specific 
metabolic rate, decreasing dietary caloric intake, inhibiting damaging species 
or increasing fidelity of DNA repair (Higami et al., 1994). 
(b) Genetic Stability and Oxidative Stress in Aging 
Inspite of the vast complexity of the aging process, relatively few mechanisms 
exist that govern the aging rate (Cutler, 1984;1992). This concept forms the basis 
of the longevity determinant hypothesis of aging. This hypothesis depends on the 
following points: 
(i) If cell dysdifferentiation represents a primary aging process, 
(ii) If reactive oxygen species cause dysdifferentiation, 
(iii) If mechanisms acting to stabilize the proper state of differentiation, such as 
antioxidants, represent a class of longevity determinants. 
The longevity determinant gene hypothesis predicts that aging is a result of 
normal biological processes necessary for life,but which have long term negative 
or aging effects on the organism (Cutler, 1975;1978). These normal biological 
processes are broadly classified as: 
(i) Developmentally-linked biosenescent processes 
(ii) The continually-acting biosenescent processes 
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The longevity of a species is therefore related to how efficiently the aging effect 
of these common problems are reduced. 
ROS generated during normal oxidative metabolism interacts with the cell's 
genetic apparatus and alters its proper state of differentiation. These changes 
occurring during normal aging, is called dysdifferentiation, leading to aging and 
cancer (Cutler, 1991a). There is much evidence to support dysdifferentiation as a 
primary cause of aging and the involvement of ROS in it (Table 2). Dysdifferentiation 
may cause increase in improper gene expression with age as in the case of c-myc 
expression and may furtherbe caused by genetic alterations. It appears possible that 
such alterations may accumulate with age in normal tissue, increasing the probability 
steadily with age of the transformation of every cell in the tissue (Semsei et al., 
1989a; Tlstye/Of/., 1995). 
Cutler (1985b) proposed that longer-lived species had a larger number of 
protective mechanisms resulting from genetic changes occurring in regulatory 
genes. The data showed that humans did have higher levels of superoxide dismutase 
proportional to the amount of oxygen used. Another assay showed that the rate of 
autooxidation of brain tissue was least in humans. It would be appropriate to assume 
that these tissues would have a lower level of oxidative damage. Cutler (1985b) has 
indeed demonstrated a lower steady state level for 8-OH-dG in longer-lived 
species compared to short-lived ones. This could be due to the fact that high levels 
of antioxidants have been found in human tissue (Cutler, 1992). The comparative 
levels of antioxidants, DNA damage and urine levels of oxidized nucleosides 
together support the importance of oxidative damage as a cause of aging. 
22 
TABLE 2 
Evidence Supporting ROS as a Possible Causative Factor 
in Dysdifferentiation 
1. Low concentration of mutagenic/carcinogenic agents induce improper gene regu-
lation, some by induction of transposable elements involved in control of gene 
expression. 
2. ROS react with chromatin, oxidize specific DNA bases and cause single-strand 
DNA breaks. 
3. ROS induce chromosomal aberrations, and longer lived species have a slower rate 
of accumulation of chromosomal aberrations. 
4. Longer-lived species show a slower rate in accumulation of lipofiiscin age-
pigments. 
5. Aging rate is proportional to metabolic rate (cal/g/day) for many different mamma-
lian species. 
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(c) Oxidative Mitochondrial DNA Damage and Aging 
Harman (1972) first proposed the role of fi^ee radicals in mitochondrial 
damage and consequent senescence. It has been shown that aging indeed results in 
some decrease in the number of mitochondria and the organelles found in older 
cells undergo some biochemical alterations. A reduction in amount of oxygen in the 
respiratory chain of inner mitochondrial membrane is accompanied by the formation 
of superoxide radical depending on the metabolic state of the organelles (Flohe, 
1982). Table 3 shows a series ofbiosenescent hypothesis on the role of mitochondria 
and its damage in aging. 
It has been proposed that aging is caused by injury to mitochondrial DNA 
(mtDNA) and lipid peroxidation by free radicals from the inner mitochondrial 
membrane (Miquel et al., 1980; Richter, 1992; Itoh et al., 1994; Sohal and Dubey, 
1994; Bagchi et al., 1995; Richter, 1995). Fast replicating cells do not suffer free 
radical attack because of their lower levels of oxygen utilization. Irreversibly 
differentiated cells, such as neurons, suffer mitochondrial aging owing to high 
levels of oxygen utilization. Mitochondria from short-lived species generate large 
amounts of ROS than long-lived species (Ku et al., 1993). Damage to mtDNA, 
therefore,would block mitochondrial turnover and replication, with concomitant 
peroxidative membrane breakdown and replication, autophagic digestion of 
organelles and decline in production of ATP and protein synthesis. 
8-hydroxydeoxyguanosine is again a major modified lesion present in mtDNA 
of rat liver at 16 times the level found in nuclear DNA (Richter, 1988), thus 
showing a high degree of oxidative damage to mtDNA. Studies suggest the lack of 
adequate repair mechanisms in mtDNA (Fukanaga and Yieding, 1979), specifically 
the repair of strand breaks. The potential for intrinsic mitochondrial mutagenesis 
clearly exists. 
24 
TABLE 3 
Mutations of Mitochondrial Genome and its Role in Aging* 
Proposed cause of aging Refe rence 
Free radical injury to mitochondria and their 
DNA. 
Free radical or lipid peroxide induced 
inactivation of the mitochondrial DNA (mtDNA) 
of fixed mitotic cells. 
Harman(1972); 
Shapira et al., 
(1989) 
Miquel et ai, 
(1980) 
Irreversible injury to mtDNA. Fleming et al., 
(1982) 
Changes in the inner membrane because of 
free radical effects on both nuclear and 
mtDNA. 
Harman(1983) 
Intrinsic mitochondrial mutagenesis in 
terminally differentiated cells. 
Nuclear accumulation of mtDNA fi"agments. 
Miquel and 
Fleming (1984) 
Richter(1988) 
'From Miquel, J. (1991) Arch. Gerontol. Geriatr. 12, 99-177. 
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Studies on differentiated cells of Drosophila muscle and mammalian 
hepatocytes and neurons indicate a senescent change in the amount and/or structure 
of mitochondrial populations (Miquel and Fleming, 1986). The activity of cytochrome 
oxidase, often used as a marker enzyme for the mitochondrial inner membrane, 
shows a senescent decline in mitochondria of liver and striated muscle (Miquel and 
Fleming, 1986). A senescent decline in extractable mtDNA was observed in 
Drosophila (Mzs,s,\Q et al., 1975) and liver of Fisher rats (Stocco andHutson, 1978). 
Changes in mtDNA structure, characterized by an increase in dimeric catenated 
forms and appearance of DNA with altered ethidium bromide intercalation in aging 
mice and rats have been reported (Murray and Balcavage, 1982). Also, an age 
dependant increase in frequency of circular dimers was seen in mtDNA of brain, 
heart, kidney and liver of rats and mice (Piko et al., 1984). 
(d) Antioxidants and Aging 
Cells are well protected by a series of antioxidants such as vitamin E, C, 
quinones, glutathione etc. and antioxidant enzymes like superoxide dismutase 
(SOD), catalase (CAT) and glutathione peroxidase (GSH-peroxidase or GPx) 
(Ballmer et al., 1994) to counter oxidative DNA damage. The levels and activities 
of SOD and GPx are much higher in long-living species than in short-living ones 
(Cutler, 1991b). This is very clear from the rate of autooxidation in brain 
homogenates assayed by the level of malonaldehyde accumulation (Cutler, 1985b). 
The rate of oxidation was least in humans and most in mice. No decrease in activity 
of GPx was observed with increasing age of rats (Santa Maria and Machado, 1987). 
In cultured fibroblasts, activities of CAT and SOD were not changed in old cells 
compared to young ones (Remade et al., 1980). Conflicting results are reported 
with increase (Sohal et al., 1990), decrease (Rao et al., 1990a) or unchanged 
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(Semsei et al., 1991;Grigolo etal., 1994) activities of SOD, increased (Sohale/a/., 
1990), decreased (Rao e^fl/., 1990b) or unchanged (Ansari e/fl/., 1989) for CAT and 
increased or unchanged (Benzi et al., 1989) for GPx. GPx is the only enzyme which 
shows no decrease during aging, while SOD was also found unchanged (Kurobe et 
al., 1990), with activities increasing in aged rats (Hiramatsu et al., 1992). In the 
case of human skin fibroblasts, there was no age-related variation in SOD (Gutman 
et al., 1987). The dismutase activity was found to be stable in subjects less than 65 
years of age and decreased slightly in the elderly (Guemouri et al., 1991). GPx 
activities increased in young adults becoming stable in adults under 65 years and 
declined in older persons (Artur et al., 1992). Variations in CAT were found to be 
similar to SOD and in agreement with earlier reports (Perrin et al., 1990; Schafer 
and Thorling, 1990). Administration of large amounts of antioxidants (vitamins A, 
E) and nutrients increases the average life expectancy of animals (Duthie et al., 
1996). Selenium is an important trace element for GPx activity and acts as a 
protective agent against the toxic effect of hydroperoxides. Low levels of selenium 
have been implicated in carcinogenesis (Combs, 1985), hepatic lesions and coronary 
heart disease. Selenium supplementation has been reported to increase longevity 
and its supplementation in elderly would be beneficial (Simonoff e/ al., 1992). 
Vitamins A and E also play an important role in premature infants, parenteral 
nutrition, elderly people and cancer patients. Vitamin E deficiency leads to lowered 
erythrocyte life span, neurological dysfunction and certain forms of cancer (Trickier 
and Shklar, 1987; Knekt, 1988), cardiovascular diseases (Gey et al., 1987) and 
impaired immune response (Boxer, 1986). Vitamin E deficiency causes alterations 
in macrophage membranes, lowered interleukin-2 production and production of 
prostaglandins is altered (Meydani et al., 1986). Higher levels of vitamin E is 
associated with lower incidence of infections in healthy adults over 60 years of age 
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(Chevance et al., 1985). These studies suggest that elderly individuals might 
benefit from a supplementation of vitamin E. Vitamin A is required for growth, 
reproduction, vision, immune processes and for its inhibitory effect on 
carcinogenesis. Low serum retinol levels have been reported to be associated with 
an increase in risk of cancer (Kark et al., 1981) or no association (Willett et al., 
1984). Simonoff e/ al. (1992) have reported the protective effect of vitamin A and 
6-carotene against cancer. Supplementation of vitamin A would be beneficial but 
care should be excercised to prevent toxic hypervitaminosis A. 
Cancer 
It is becoming increasingly apparent, that cancer development is a stepwise 
process involving altered populations at many steps (Farber and Cameron, 1980; 
Potter, 1983). These new cell populations act as the site of origin for yet another 
new or altered non-cancerous cell population, and with each step, the process 
shows an increased probability of evolving ultimately into a malignant neoplastic 
population (Farber, 1984). The carcinogenic process, therefore, appears to be one 
of cellular evolution (Farber, 1973) based upon repeated selection of rare cells 
(Nowell, 1976; Farber and Cameron, 1980). 
Initiation of cancer may involve changes in DNA. This could be in terms of 
an altered base, a miscoding lesion, rearrangements of segments of DNA, the 
activation and modulation of gene expression by neighbouring base sequences, 
gene duplication and the activation of oncogenes (Cavenee and White, 1995). 
Generally, DNA repair systems work efficiently and therefore, cell proliferation 
has to occur soon after the changes in DNA for it to be effective. The initiated cells 
now expand into nodules, papillomas or polyps, one or more of which can act as a 
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population for the ultimate development of cancer. These proliferations are the 
immediate indices for promotion, although they are often only distantly related to 
the appearance of the ultimate neoplasia. Promotion may be enhanced by the 
creation of a stimulus and a selective or differential inhibition of surrounding cells 
although this is not a general phenomenon (Farber, 1984). Cancer progression is 
the stepwise process where the initiated cell, nodule, polyp or the papilloma, 
evolves into a cancer and further steps as the cancer becomes progressively more 
malignant. In the skin, it has been reported that a papilloma can act as a site for 
cancer development. In the liver, nodules have been shown to be sites of origin of 
hepatocellular carcinoma (Goldfarb, 1973; Scherer and Emmelot, 1975; Pugh and 
Goldfarb, 1978). 
It is a well known fact that viruses can cause tumors. The genes implicated 
in malignancy are often altered forms of human genes. Often, viruses activate host 
genes that are usually quiescent i.e. - the activation of proto-oncogenes into 
oncogenes, the products of which when altered or expressed contribute to 
malignancy. Apart from viruses, mutations too can convert proto-oncogenes into 
carcinogenic oncogenes. Studies revealed the presence of human c-onc genes with 
several being active (Marshall, 1985). These genes were found to be mutated, 
rearranged or unusually active in maiiy viral and non-viral tumors. Retroviruses 
lacking c-onc genes are also oncogenic, giving rise to tumors more slowly than 
those with \-onc genes (Weiss, 1986). In a majority of the cases, particularly the 
avian bursal lymphomas (ALV), the retroviral genome integrates adjacent to the c-
myc gene and in some cases, hybrid viral c-myc RNA transcripts could be 
demonstrated (Hayward et al., 1981). This integration can occur both upstream or 
downstream oi c-myc and in either orientation of the provirus (Payne et al., 1982) 
thus inducing expression of c-m>'c in B-cell lymphomas. Chromosome translocations 
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in human tumor cells brings one genes into juxtaposition with active regions for 
gene expression leading to their constitutive expression (Klein and Klein, 1984) 
and an overexpression of the same (Collins and Groudine, 1982). Cellular ras genes 
become oncogenic by point mutations resulting in single codon changes (Marshall, 
1985). Such minimal change in ras can lead to cell transformation in established 
cell lines. 
Oxidative DNA Damage and Cancer 
Reactive oxygen species (ROS) are formed continuously in living cells as a 
consequence of metabolic and other biochemical reactions as well as external 
factors (Nagashima et al., 1995). A variety of carcinogens including benzene, 
aflatoxin and benzo(a)pyrene may exert their effect partly by generating ROS 
during their metabolism (Mauthe et al., 1995; Shen et al., 1995). The generation of 
*0H leads to oxidation, deamination of DNA or nitrosation of proteins (deRojas-
Walker et al., 1995). Gamma- and X-rays also generate ROS by cleaving water to 
'OH and O ' radicals (Davies, 1987; Epe, 1991; Elkind, 1996). 
With respect to cancer, DNA is considered to be the most important target of 
ROS (Feig et al., 1994; Ames et al., 1995). Oxidative damage to DNA includes a 
range of specifically oxidized purines and pyrimidines as well as alkali labile sites 
and strand breaks, formed directly or by repair processes (Dizdaroglu, 1994; Breen 
and Murphy, 1995). 
DNA damage in vivo is constantly repaired by a variety of enzymes. Strand 
breaks are annealed and modified bases are excised out as such or as nucleotides 
(Demple and Harrison, 1994). Defects in DNA repair systems are primarily 
responsible for several human diseases (Digweed, 1993) and some of these have 
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been shown to have increased cancer risk and increased levels of oxidative DNA 
damage (Fig. 1). 
Oxidative modifications of DNA bases can lead to mutations if left unrepaired 
or repaired with errors before replication. Studies show that although all the four 
bases are modified by ROS, the mutations are usually related to modifications of 
GC basepairs, while modifications of AT basepairs rarely lead to mutations (Retel 
et al., 1993). These mutations are mainly base pair substitutions, whereas base 
deletions, large deletions and insertions are less frequent. The'OH from ionizing 
radiations generally induce GC to CG or AT basepair substitutions (Retel et al., 
1993), while singlet oxygen preferentially induces 8-oxo-dG and GC to AT 
substitutions (Epe, 1991; Emmerit et al., 1995). While modified guanine like 
8-oxo-dG and apurinic sites are mispaired mainly with adenine (Shibutani et al., 
1991; Kamiya et al., 1995), modified adenine does not seem to mispair or lead to 
mutations (Cheng et al., 1992). In human tumors, G to T transversions are among 
the most frequent hot spot mutations in the p53 suppressor gene (Hollstein et al., 
1991; Harris and Hollstein, 1993). In addition to the mutations related to mispairing 
of oxidized bases, ROS may also cause reduced fidelity of DNA polymerase B 
(Feig and Loeb, 1993) and alter the methylation of cytosine and thus gene control 
(Weitzman et al., 1994). 
A role for ROS in the development of cancer in humans is further supported 
by the abundant presence of oxidative DNA modifications in cancer tissue (Ames 
et al., 1993b). Thus, lungs from cancer patients contain 25-75 8-oxo-dG per 10' 
deoxyguanosine in the apparently normal tissue and two to three fold higher values 
in the tumor (Olinski et al., 1992). Cigarette smoking is actively associated with 
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lung cancer. Exposure of cell cultures to cigarette smoke causes accumulation of 8-
oxo-dG (Fraga et al., 1990). Presumably, there is a sequence of smoking related 
events required for production of lung cancer, which may involve mutations by 
components of cigarette smoke, some of which may be mediated by ROS. Urine and 
sperm of smokers contain 4-10 fold elevations in altered nucleotides and 8-oxodG 
and its excretion in urine has been consistently shown to increase by 30-50% (Inoue 
et al., 1993; Loft et al., 1994). The mechanism of oxidative stress may involve, 
both, an increase in the rate of metabolism with an increase in mitochondrial 
production of ROS in the cells as well as the presence of ROS and ROS-generating 
compounds in the smoke. 
Hepatocellular carcinoma is a major cause of cancer mortality and may be 
associated with ingestion of aflatoxin (Ross et al., 1992) or chronic infection of 
hepatitis B or C (Blumberg et al., 1975; Hagen et al., 1994). A spectrum of different 
nucleotide substitutions has also been reported in p53 (Nishida et al., 1993). G to 
T transversions are the major mutations produced by aflatoxin lesions and ROS 
damage to DNA (McElride et al., 1991). The 8-oxo-dG and other oxidative DNA 
modifications have been reported to accumulate in tumor tissue in hepatocellular 
cancers (Ogawa et al., 1995; Wang et al., 1995). Accumulation of 8-oxo-dG in liver 
tissue and the consequent carcinoma developed by etinyl estradiol have been 
reduced by antioxidants, vitamin C, E and B-carotene (Ogawa et al., 1995). 
Prostate cancer is characteristically diagnosed in old age and commences in 
most males by the age of 40 years. The late presentation of the carcinoma, however, 
.suggests a multistep involvement in tumorigenesis. The paucity of known chemical 
agents associated with prostate cancer indicates an association with endogenous 
cellular processes (Feig et al., 1994), with ROS being the most plausible agent. 
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Further studies are required to identify the DNA lesions associated with this cancer 
and determine the mechanism of their formation. 
Of the total incidence of cancer in women, breast cancer represents about 
25-29% and accounts for 15-18% of mortality (Pasqualine, 1994). Breast cancer 
may be caused by xenobiotic-induced structural alterations in DNA bases that 
affect DNA-synthesis (Kuchino et al., 1987). It is reported that elevated levels of 
8-oxo-dG adducts in DNA play a fundamental role in breast cancer (Malins and 
Haimanot, 1991) and high levels of 8-oxo-dG and 8-hydroxyadenosine compared to 
the normal tissue (Malins et al., 1993, 1995; Musarrat et al., 1996). Evidence also 
exists for OH modification of DNA being intimately involved in the progression of 
breast tumors to the metastatic stage and is an important etiologic factor (Malins et 
al., 1996). 
Exposure and cellular production of ROS is a product of normal metabolism. 
Although a large number of protective mechanisms, from antioxidants to DNA 
repair enzymes exist, resulting oxidative DNA damage is abundant in human 
tissues. A concept of balance between metabolic/physiological functions and 
deleterious effects has emerged as the basis for the development of degenerative 
diseases, including cancer. The data obtained from human studies do support the 
notion that oxidative DNA damage is an important mutagenic and apparently 
carcinogenic factor (Loft and Poulsen, 1996). 
Scope of the Thesis 
The literature shows that oxidative damage to DNA is the primary or one 
among the many events leading to degenerative diseases, including cancer and 
aging. DNA damage is studied by a variety of methods, including gas 
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chromatograpliy/mass spectroscopy (GC-MS), HPLC and electrochemical detection 
(EC). All these methods detect oxidized bases and nucleotides, such as 8-oxodG. 
Nucleotides are also detected by "P-postlabelling and radiometric detection. 
Immunochemical methods involve estimation of 8-oxodG by slot blot and ELISA 
using polyclonal antibodies against UV-DNA and 8-oxodG. This thesis reports the 
use of monoclonal antibodies against ROS-DNA as a probe to detect oxidative DNA 
damage to the human genomic DNA. 
Calf thymus DNA was purified free of proteins and single-stranded regions. 
The purified DNA was partially digested with micrococcal nuclease and fractionated 
by gel filtration. Native and 400 bp (approximate size) calf thymus DNA was 
modified with 'OH. The native and 400 bp ROS-DNA were characterized by UV 
spectroscopy, thermal denaturation studies, sedimentation in alkaline sucrose density 
gradients, nuclease SI digestibility and hydroxyapatite chromatography. DEAE 
Sephadex A-25 was used to quantify base modifications in ROS-DNA. Native ROS-
DNA was used to generate polyclonal antibodies in goat, while the 400 bp ROS-
DNA was used to generate monoclonal antibodies. The polyclonal and monoclonal 
antibodies were characterized for their fine antigenic specificity. It was observed 
that the monoclonal antibody had higher affinity for ROS-modified epitopes on 
nucleic acids, polydeoxyribonucleotides and bases and consequently used as an 
immunochemical probe to detect oxidative damage to DNA (by ELISA), isolated 
from cancer patients and normal healthy population of different age groups. The 
reactivity of antibodies in the sera of both the groups - cancer patients and the aged 
population, was determined by inhibition ELISA, with native (unmodified) and 
ROS-DNA. 
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MATERIALS 
Calf thymus DNA, nuclease SI, micrococcal nuclease, bovine serum albumin, 
anti-human-, anti-mouse- and anti-goat-IgG-alkaline phosphatase conjugates, 
ethidium bromide, Coomassie Brilliant Blue G250 and R250, sodium dodecyl 
sulphate, Tween-20, Millipore filter (0.45 i^M pore size), Freund's complete and 
incomplete adjuA'ants, methylated bovine serum albumin, lambda DNA EcoRI and 
Hindlll digest, polydeoxyribonucleotides, anti-mouse IgG and IgM sub-classes, 
pristane, HAT and standard protein markers were purchased from Sigma Chemical 
Company. U.S.A. Synthetic polynucleotides, Sepharose 4B, DEAE Sephacel, 
DEAE Sephadex A-25, agarose, FicoU 400, Protein G-Sepharose 4B were obtained 
from Pharmacia Fine Chemicals, Sweden. Folin-Ciocalteu reagent, p-nitrophenyl 
phosphate and Blue Dextran 2000 were purchased from Centre for Biochemical 
Technology, New Delhi. Foetal calf serum, Dulbecco's Modified Eagles Medium 
(DMEM) were from Biological Industries, Israel. 
Polystyrene microtitre flat bottom ELISA plates having 96 wells (7 mm 
diameter), cell culture plates (6, 12 and 96 wells), culture flasks (50 and 250 ml) 
were purchased from Nunc, Denmark. Acrylamide, ammonium persulphate, 
bisacrylamide, hydroxyapatite, N,N,N',N'-tetraethyl methylene diamine (TEMED) 
were from Bio-Rad Laboratories, U. S. A. EDTA (disodium salt), hydrogen peroxide, 
chloroform, phenol were from Qualigens, India. Diphenylamine and ethanol were 
chemically pure. All other reagents /chemicals were of highest analytical grade 
available. 
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EQUIPMENT 
Bausch and Lomb Spectronic 20, Shimadzu UV-240 spectrophotometer 
equipped with thermo-programmer and controller unit, ELISA microplate reader 
MR-600 (Dynatech, U.S.A.). Elico pH meter Ll-IOT, Ultraviolet lamp (Vilber 
Lourmat,France). Agarose gel electrophoresis assembly GNA-100 (Pharmacia, 
Sweden), Beckman ultracentrifuge, Avanti 30 table top high speed refrigerated 
centrifuge (Beckman, U.S.A.), Polyacrylamide gel electrophoresis assembly (Bio-
Rad, U.S.A.),Transblot assembly (Bio-Rad, U.S.A.), CO^-incubator (Heraeus 
Instruments, Germany), light microscope (Olympus, Japan) were the major 
equipment used in this study. 
COLLECTION OF SERA AND BLOOD SAMPLES 
Sera and blood were collected from normal human subjects and cancer 
patients proven with histopathological diagnosis and normal healthy individuals of 
different age groups. Sera were decomplemented at 56°C for 30 min and stored in 
aliquots at -20°C. Lymphocytes were isolated by centrifugation at 2000 rpm after 
lysing erythrocytes by RBC lysing solution. The lymphocytes were stored at -80°C 
for further use. 
METHODS 
Determination of DNA Concentration 
DNA concentration was determined by the method of Burton (1956). 
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(a) Crystallization of diphenylamine 
Diphenylamine (2 g) was dissolved in 200 ml boiling hexane. Approximately 
0.5 g of activated charcoal was added. After filtering the hot mixture through 
Whatman No.l filter paper, the filtrate was kept overnight at 4°C. Diphenylamine 
crystals so obtained, were again filtered to remove hexane and finally dried at room 
temperature. 
(b) Preparation of diphenylamine reagent 
Recrystallized diphenylamine (750 mg) was dissolved in 50 ml glacial acetic 
acid containing 0.75 ml concentrated sulphuric acid. 
(c) Procedure 
One ml of 1 N perchloric acid was added to 1.0 ml of DNA sample and 
incubated at 70°C for 15 min. One hundred \il of 5.43 mM acetaldehyde was added 
followed by 2 ml of freshly prepared diphenylamine reagent. The contents were 
mixed and incubated at room temperature for 16-20 hr. Absorbance was read at 600 
nm. The concentration of DNA in unknown samples was determined from a 
standard plot of purified calf thymus DNA. 
Determination of Protein Concentration 
Protein was estimated by the methods of Lowry et al. (1951) and Bradford 
(1976). 
38 
Protein estimation by Folin's-phenol reagent 
The protein estimation by this method utilizes alkali (to keep the pH high), 
Cu^^  ions (to chelate proteins) and tartarate (to keep the Cu^* ions in solution at 
high pH). 
(a) Folin-Ciocalteu reagent 
The reagent was purchased from Centre for Biochemical Technology, New 
Delhi and diluted 1:4 with distilled water before use. 
(b) Alkaline copper reagent 
The components of alkaline copper reagent were prepared as follows-
(i) Two per cent sodium carbonate in 100 mM sodium hydroxide 
(ii) 0.5 per cent copper sulphate in 1 per cent sodium potassium tartarate 
The working reagent was prepared freshly before use by mixing components 
(i) and (ii) in the ratio 50:1. 
(c) Procedure 
To 1 ml of protein sample, was added 5 ml of alkaline copper reagent, mixed 
thoroughly and allowed to stand for 10 min. Working Folin-Ciocalteu reagent (1 ml) 
was added to the tubes, mixed and incubated for 30 min at room temperature. The 
absorbance was read at 700 nm. The concentration of protein in unknown sample 
was determined from a standard plot of bovine serum albumin. 
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P r o t e i n Es t imat ion by Dye-Binding Method 
This assay is based on colour change when Coomassie Brilliant Blue G250 in 
acidic medium, binds strongly to protein hydrophobically and at positively charged 
groups (Bradford, 1976). In the environment of these positively charged groups, 
protonation is suppressed and a blue colour is observed ( A, ^ - 595 nm). 
( a ) Dye p r e p a r a t i o n 
One hundred mg Coomassie Brilliant Blue G250 was dissolved in 50 ml of 
95% ethanol. To this solution was added 100 ml of 85% (v/v) orthophosphoric acid. 
The resulting solution was diluted to a final volume of 1 litre. 
(b) Protein assay 
To solutions containing 10 - 100 jig protein was added 5 ml of dye solution 
and contents mixed by vortexing. The absorbance was read at 595 nm after 5 min 
against a reagent blank. 
Purification of Calf Thymus DNA 
Commercially obtained calf thymus DNA was dissolved in 0.1 M SSC (15 
mM sodium citrate and 150 mM sodium chloride), pH 7.3. The DNA (2 mg/ml) was 
then mixed with an equal volume ofchloroform-isoamyl alcohol (24:1) in a stoppered 
cylinder and shaken for 1 hr. The aqueous layer containing DNA was separated 
from the organic layer and reextracted with chloroform-isoamyl alcohol. The DNA 
was precipitated with two volumes of cold absolute ethanol and collected on a glass 
rod. After drying in air, the DNA was dissolved in 30 mM acetate buffer, pH 5.0 
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containing 30 mM zinc chloride and treated with nuclease SI (150 units/mg DNA) 
at 37°C for 30 min to remove single stranded regions. The reaction was stopped by 
adding one-tenth volume of 200 mM EDTA, pH 8.0. The nuclease SI treated DNA 
was extracted twice with chloroform-isoamyl alcohol and finally precipitated with 
two volumes of cold ethanol. The precipitate was dissolved in phosphate-buffered 
saline (PBS) (10 mM sodium phosphate containing 150 mM sodium chloride), pH 
7.4. 
Fragmentation of Purified Native Calf Thymus DNA 
Micrococcal nuclease was used to digest purified DNA to obtain smaller 
fragments (Ali et al., 1985). Purified DNA (2 mg/ml) in 6 mM Tris, 100 mM NaCl 
and 2 mM CaCl^, pH 8.0 was treated with 0.25 units of micrococcal nuclease per mg 
DNA at 37°C for 6 min. The reaction was stopped by adding one-tenth volume of 
200 mM EDTA,, pH 8.0. The mixture was extracted twice with chloroform-isoamyl 
alcohol and fragmented DNA was precipitated with cold absolute ethanol and 
dissolved in 30 mM acetate buffer, pH 5.0 containing 30 mM ZnCl^. The DNA was 
digested with nuclease Sj (150 units/mg DNA) at 37°C for 30 min. The reaction was 
stopped with one-tenth volume of 200 mM EDTA, pH 8.0. The digested DNA 
fragments were extracted twice with chloroform-isoamyl alcohol and precipitated 
with cold absolute ethanol. The DNA fragments were then dissolved in Tris-
buffered saline (TBS), pH 8.0 and separated on the basis of size by gel filtration on 
a Sepharose 4B column (46.0 cm x 1.2 cm) equilibrated with TBS and fractions of 
4 ml were collected. The size of the DNA fragments was determined by 
polyacrylamide gel electrophoresis (PAGE). 
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Polyacrylamiide Gel Electrophoresis 
DNA fragments obtained after digestion with micrococcal nuclease and gel 
filtration were subjected to PAGE to determine their size under non-denaturing 
conditions as described by Laemmli (1970). 
(a) Buffer and other reagents 
(i) Acrylamide-bisacrylamide (30:0.8) 
s 
A stock solution was prepared by dissolving 30 g of acrylamide and 0.8 g 
of bisacrylamide in distilled water to a final volume of 100 ml. 
(ii) Resolving gel buffer 
A stock solution of Tris (3 M) was prepared by dissolving 36 g in 48 ml of 1 
N HCl. The pH was then adjusted to 8.8 and final volume made upto 100 ml with 
distilled water. 
(Hi) Electrode buffer 
The electrophoretic buffer used was TAE, pH 7.9 (40 mM Tris, 1.14 ml 
glacial acetic acid and 1 mM EDTA). 
(b) Procedure 
The PAGE assembly was set up and plates sealed with 1% agarose from the 
sides and bottom. The non-denaturing gel was prepared and poured between the 
glass plates separated by 1.5 mm thick spacer and allowed to polymerize at room 
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temperature.Two \ng DNA samples were mixed with one-tenth volume of stop mix 
(30% Ficoll, 0.025% Xylene Cyanole FF and 500 mM EDTA in 10 times concentrated 
TAE buffer) and applied onto the gel. The gel was run for 8 - 10 hr at room 
temperature at 80 Volts, stained with ethidium bromide (0.5 fig/ml) and visualized 
under UV light. DNA fragment size was determined from marker DNA of lambda 
DNA double digest with EcoRI and Hindlll. 
Recipe for 7.5% PAGE 
Acrylamide-bisacrylamide 
Resolving gel buffer 
1.5% Ammonium persulphate 
Distilled water 
TEMED 
10.0 ml 
5.0 ml 
1.5 ml 
23.5 ml 
20.0 \LI 
PAGE for Proteins 
A 7.5% separating gel was layered with 2.5% stacking gel according to the 
composition given below. 
Solutions Stacking gel Resolving gel 
Acrylamide-bisacrylamide 
Stacking gel buffer 
Resolving gel buffer 
Distilled water 
10% SDS 
1.5% Ammonium persulphate 
TEMED 
2.5 ml 
5.0 ml 
11.3 ml 
0.2 ml 
1.0 ml 
15 jil 
7.5 ml 
3.75 ml 
16.9 ml 
0.3 
1.5 
15 
ml 
ml 
M 
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The gel was cast in the proportion of reagents given. The protein samples 
containing 10% glycerol and 0.002% bromophenol blue were applied and 
electrophoresed at 70 Volts for 6-8 hr using Tris-glycine buffer (25 mM Tris, 192 
mM glycine containing 1% SDS), pH 8.3. The gels were stained overnight with 
0.1% Coomassie Brilliant Blue R250 (in 25% isopropanol and 10% glacial acetic 
acid). Destaining was carried out with a mixture of 30% methanol and 10% glacial 
acetic acid. 
Reactive Oxygen Species Modification of DNA 
Aqueous solution of native and 400 bp (approximate size) calf thymus DNA 
(0.15 mM bp) in PBS, pH 7.4 were irradiated under 254 nm light for 30 min at room 
temperature in the presence of hydrogen peroxide (15.1 mM). Excess of hydrogen 
peroxide was removed by extensive dialysis against PBS, pH 7.4. DNA samples 
exposed to hydrogen peroxide or UV light alone served as controls. 
Spectroscopic Analysis 
The ultraviolet spectra of modified and unmodified DNA were recorded in 
the wavelength range of 200-400 nm on a Shimadzu UV-240 spectrophotometer. 
Absorption Temperature Scan 
Thermal denaturation analysis of nucleic acids was performed in order to 
ascertain the degree of modification incurred on the nucleic acids by determining 
mid-point melting temperature (T^). Native and modified DNA samples were 
subjected to heat denaturation on a Shimadzu UV-240 spectrophotometer coupled 
with a temperature programmer and controller assembly (Hasan and Ali, 1990). All 
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the samples were melted from 30°C to 95°C at a rate of 1.5°C/mm after 10 min 
equilibration at 30°C. The change in absorbance at 260 nm was recorded with 
increasing temperature. Percent denaturation was calculated as follows: 
Percent denaturation = xlOO 
Where, A^ = absorbance at a temperature T°C 
A^ = final maximum absorbance on the completion of denaturation 
Ajjj = initial absorbance at 30°C 
Hydroxyapatite Column Chromatography 
Hydroxyapatite column chromatography was employed to discriminate nucleic 
acids endowed with different secondary structures. Native and ROS-DNA (in 10 
mM Na-phosphate buffer, pH 6.8) were chromatographed on hydroxyapatite as 
described by Dardalhon and Averback (1988). Batch elution was carried out with 
125 mM and 250 mM Na-K-phosphate buffer, pH 6.8 at a flow rate of 15 ml/hr and 
fractions of 3 ml v/ere collected and absorbance monitored at 260 nm. 
Detection of Single Strand Breaks 
The damage to DNA by hydroxyl radical was ascertained by alkaline sucrose 
density ultracentrifugation and nuclease SI digestibility. 
(a) Alkaline sucrose density gradient ultracentrifugation 
Native and ROS-DNA (0.2 ml) were treated by the addition of an equal 
volume of 0.2 N NaOH. After 10 min to allow denaturation of DNA, 0.4 ml sample 
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was layered on top of a linear 4.6 ml alkaline sucrose gradient (5-20% sucrose 
containing 0.1 N NaOH and 10 mM EDTA) (AH and Sauerbier, 1978). The 
gradients were centrifuged at 30,000 rpm for 1 hr at 20°C in a swinging bucket SW 
50.1 rotor (Beckman ultracentrifiige). The bottom of the tubes were pierced and six 
drop fractions were collected, diluted to 0.5 ml with distilled water and 
absorbance monitored at 260nm. 
(b) Nuclease SI digestibility 
Unmodified and ROS-DNA (2 jig) in acetate buffer (30 mM each of sodium 
acetate and ZnCl^), pH 5.0 were treated with nuclease SI (20 units/^g DNA) for 30 
min at 37°C (Matsuo and Ross, 1987). The reaction was stopped by adding one-
tenth volume of 200 mM EDTA, pH 8.0. The digested samples were then subjected 
to electrophoresis on 0.8% agarose. 
(i) Gel preparation 
Agarose (0.8%) in TAB buffer was dissolved by heating. The solution was 
cooled to 50°C and then poured into the gel tray and allowed to solidify at room 
temperature. 
(ii) Sample preparation and loading 
Samples of nucleic acids digested with nuclease SI were mixed with one-
tenth volume of sample buffer (0.125% bromophenol blue, 30% Ficoll 400, 500 mM 
EDTA in lOx electrophoresis buffer). The samples were loaded in the wells and 
electrophoresed for 2 hr at 30 mA. The gels were stained with ethidium bromide 
(0.5 ng/ml), visualized under UV light and photographed. 
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Separat ion and Quantitat ion of DNA Bases 
The separation and quantitation of bases in modified and unmodified DNA 
was done according to the method described by Hasan and Ali (1990). 
( a ) Acid hydrolys i s of DNA samples 
Native and 400 bp ROS-DNA and unmodified DNA samples were precipitated 
with two volumes of cold ethanol and dissolved in 70% perchloric acid. The 
samples were heated at 100°C for 1 hr to release the bases. The hydrolysate was 
neutralized and chromatographed on DEAE Sephadex A-25 matrix. 
( b ) D E A E Sephadex A-25 column chromatography 
The swollen ion exchanger was suspended in the equilibrating buffer (1 mM 
Tris-HCl, pH 7.6) and poured in a column. The column was extensively equilibrated 
and 3 ml of sample was applied and eluted with a linear gradient of 1 - 20 mM Tris-
HCl, pH 7.6 at a flow rate of 40 ml/hr. Fractions of 3 ml were collected and 
absorbance recorded at 260 nm. Elution profiles of individual bases and hydrolyzed 
native DNA served as standards. 
Immunization Schedule 
Native ROS-DNA (100 ng) was complexed with an equal amount (w/w) of 
methylated BSA and emulsified with an equal volume of complete Freund's adjuvant 
and injected intramuscularly in goat. Subsequent injections were given in incomplete 
Freund's adjuvant. A total of 600 jig of ROS-DNA was injected during the course 
of six injections. Blood was collected from the jugular vein, serum separated and 
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decomplemented at 56°C for 30 min. Pre-immune serum was collected prior to 
immunization. The sera were stored in small aliquots at -80°C with 0 .1% sodium 
azide as preservative. 
Isolation and Purification of IgG 
(a) Precipitation of immunoglobulins 
Heat decomplemented serum was precipitated by saturated ammonium 
sulphate (SAS) solution. To 6.5 mlof serum was added 3.5 ml of SAS to give a final 
ammonium sulphate concentration of 35%. The solution was stirred gently for 1 hr 
at 4°C and centrifuged at 4000 rpm for 15 min. The precipitate was washed once 
with SAS and dissolved in 10 mM sodium phosphate buffer, pH 8.0 and excess 
ammonium sulphate was removed by extensive dialysis against 10 mM Na-phosphate 
buffer, pH 8.0. 
(b) D£A£ Sephacel chromatography 
Crude immunoglobulins dissolved in 10 mM Na-phosphate buffer, pH 8.0 
was applied and bound at the rate of 10 ml/hr, to DEAE Sephacel column 
(20 cm X 1.5 cm) previously equilibrated with the same buffer. The column was 
washed to remove unbound material until absorbance at 280 nm was near base line 
value. The bound IgG was eluted with five volumes of 10 - 300 mM gradient of Na-
phosphate buffer, pH 8.0. Fractions of 3 ml were collected and monitored at 
280 nm. The homogeneity of the isolated IgG was confirmed by a single band in 
SDS-PAGE. 
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Immunoaffinity Purification of IgG 
(a) CNBr acltivation of Sepharose 4B 
Fifteen ml of commercially available Sepharose 4B was suspended in distilled 
water, filtered and washed with 300 ml of cold distilled water on a sintered glass 
funnel. Moist gel (about 10 g) in 10 ml of 2 M sodium carbonate was kept in ice-
NaCl bath placed on a magnetic stirrer. One gram of cyanogen bromide in 0.8 ml of 
acetonitrile was slowly added to the gel with gentle stirring. The reaction was 
allowed to proceed for 12 min and the reaction product filtered on sintered glass 
funnel, washed with 400 ml cold 100 mM sodium carbonate and resuspended in the 
same buffer. The filtrate (unreacted CNBr) was treated with ferrous sulphate to 
convert it into harmless ferrocyanide. All steps were carried out in a fume hood 
chamber (Ali, 1984). 
(b) Poly-L-lysine coupling to activated Sepharose 4B 
Poly-L-lysine was coupled to CNBr activated Sepharose 4B following the 
method of Wilchek (1973). Immediately after CNBr activation of the gel, an equal 
volume of poly-L-lysine (100 mg in 10 ml of 100 mM sodium bicarbonate) was 
added and kept at 4°C for 12 hr with slow stirring. The buffer was drained out and 
the gel washed successively with 100 ml each of (i) distilled water (ii) 0.1 N HCl 
(iii) 100 mM sodium bicarbonate and (iv) distilled water till neutral. Finally, the gel 
was suspended in 40 ml of 150 mM acetate buffer, pH 4.5. The extent of poly-lysine 
depletion due to covalent coupling with activated Sepharose 4B was quantitated by 
TNBS estimation of lysine in the drained effluent as described by Habeeb (1966). 
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(c) Affinity isolation of anti-ROS-DNA antibodies 
Affinity matrix ROS-DNA-[poly-lysyl-Sepharose 4B] was prepared according 
to the method of Nicotra et al. (1982) with a slight modification. Freshly prepared 
poly-lysyl-Sepharose 4B (20 ml) was packed and equilibrated with 50 ml acetate 
buffer, pH 4.5 in a mini column (1.5 cm x 5.0 cm). ROS-DNA (700 jig) in acetate 
buffer was loaded onto the gel and unbound material was washed with 50 ml of 
PBS, pH 7.4. DEAE Sephacel purified IgG was then passed through the matrix. The 
unbound proteins were washed with PBS and bound IgG was eluted with a linear 
sodium chloride gradient of 0.15 M - 3.0 M in 10 mM Na-phosphate buffer, pH 7.4. 
The fractions were monitored at 260 and 280 nm. 
(d) Regeneration of affinity column 
The affinity matrix was regenerated several times by washing successively 
with 50 ml each of (i) distilled water (ii) 0.1 NHCl(iii) 100 mM sodium bicarbonate 
and (iv) distilled water till neutral. 
Generation of Monoclonal Antibodies Against 400 bp ROS-DNA 
Monoclonal antibodies were generated against ROS-DNA essentially 
following the method of Kohler and Milstein (1975). 
(a) Antigen 
The antigen used for generation of monoclonal antibodies was ROS-modified 
fractionated calf thymus DNA (400 bp approximate size). Four hundred bp ROS-
DNA was prepared by irradiating DNA (0.15 mM bp) under 254 nm UV light in the 
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presence of hydrogen peroxide (15.1 mM) for 30 min at room temperature. Excess 
hydrogen peroxide was removed by extensive dialysis against PBS, pH 7.4. 
(b) Immunization protocol 
(i) Bleeding 
Prior to immunization, Balb/c mice were bled from the orbital sinus and the 
pre-immune serum collected. The sera were decomplemented at 56°C and stored at 
-20°C for future use. 
(ii) Immunization 
Eight Balb/c male mice were used for immunization. The antigen, ROS-DNA 
(50 |ig/mouse) was complexed with an equal amount of methylated bovine serum 
albumin (MBSA) (w/w) and an equal volume of Freund's complete adjuvant was 
added to prepare the emulsion. The mice were then injected subcutaneously. 
Three weeks after the primary immunization, the mice were boosted 
intraperitoneally with 25 ng antigen/mouse in incomplete Freund's adjuvant. One 
week later, the mice were bled through the orbital sinus. The sera were 
decomplemented at 56°C and screened for the anti-ROS-DNA antibody response 
by ELISA. Where necessary, a second booster was given in exactly the same 
manner as the first booster. 
(c) Fusion of spleenocytes 
Spleen from the best responder mouse was fused with Sp2/0 murine myeloma 
cell line using 1 ml of 50% PEG (MW 1500) to generate antibody producing 
hybridoma. 
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(d) Materials for fusion 
(i) DM EM 
Commercially available DMEM (Biological Industries, Israel) was dissolved 
in 1 litre glass distilled water and sterilized by filtering through 0.22 ^ membrane. 
(ii) Growth medium 
DMEM was supplemented with 10% foetal calf serum (PCS). 
(Hi) HAT medium 
50x HAT stock (Sigma Chemical Company, U.S.A.) containing 5x10'^ M 
hypoxanthine; 2x10' M aminopterin and 8x10"^ M thymidine was dissolved in 10 ml 
sterile distilled water and added to 500 ml of 20% FCS-supplemented medium. 
(iv) 0.9% ammonium chloride 
0.9 g of ammonium chloride was dissolved in 100 ml distilled water. 
(v) 50% (w/v) PEG 
One gram PEG(MW 1500) was autoclaved at 121°C for 20 minin a screw cap 
glass tube to sterilize and liquify PEG. While still hot, 1 ml serum and HAT-free 
DMEM was added to it. 
(e) Fusion procedure 
The immune mouse was sacrificed by cervical dislocation. The abdominal 
wall was cut with sterile scissors and spleen exposed. The spleen was removed and 
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placed in a petri dish containing 10 ml DMEM. The spleen was teased with sterile 
forceps to release cells and single cell suspension obtained. This was transferred 
to a 50 ml sterile tube and centrifiiged at 1500 rpm for 5 min. The pellet was washed 
twice by resuspending in 20 ml serum free DMEM and centrifiiging at 1500 rpm. 
Simultaneously, the Sp2/0 myeloma cells were also harvested and washed. The 
spleen and myeloma cells were mixed and centrifuged at 1500 rpm for 5 min. To the 
pellet was added 1 ml PEG drop by drop over a period of 30 sec and mixed for 
another 30 sec. Then 5 ml medium was added slowly to the tube over a period of 
about 10 min and cell mixture was left at 37°C for 5 min. The cells were resuspended 
in about 30 ml HAT medium and dispensed into six 24 - well culture plates. The 
plates were then incubated at 37°C in humidified 5% CO^ incubator. 
(f) Selection of hybrids 
The culture plates were examined daily for colony growth and condition of 
the medium (colour). After 4-5 days of fusion, the wells were fed with fresh HAT 
medium. This was done by removing 0.5 ml of medium from each well and adding 
the same amount of fresh HAT medium. The plates were again examined for the 
next 5-7 days. When colonies were macroscopic and medium was turning yellow, 
the plates were screened for the antibody activity. 
(g ) Screening of hybrids 
The supernates from wells harbouring hybrids were screened for antibody 
activity against ROS-DNA by ELISA. The plates were replenished with fresh 
medium. Wells were reassayed again after 3-4 days to confirm antibody secretion. 
The cells from hybrids producing the desired antibodies were expanded, cloned 
and frozen in liquid nitrogen. 
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(h) Cloning of hybrids 
Cloning of hybrids was done by the technique of limiting dilution. The hybrid 
cells were counted and suitably diluted in medium to obtain 50 cells. These were 
mixed with 20 ml of 10% DMEM containing approximately 25 x 10* spleen cells 
(feeder cells) and 200 i^l were dispensed in each well of a 96-well flat-bottom 
culture plate. The plates were then incubated at 37°C in 5% CO^. Colonies of cells 
were visible after 10 -12 days and supernates were screened for specific antibodies. 
The cloning was done twice to ensure monoclonality. 
(i) Maintenance of hybrids 
The hybrid cells were periodically harvested by centrifixgation and stored in 
liquid nitrogen. This was done by adding 1 ml freezing medium (90% FCS +10% 
DMSO) and transferring this to 2 ml cryotubes. The tubes were first wrapped in 
cotton and left overnight at -70°C. Vials were transferred into liquid nitrogen the 
next day. 
(j) Thawing of cells 
The cryotube was removed from liquid nitrogen and cleaned with 70% 
alcohol. Cells were thawn immediately by adding 1-2 ml medium (37°C). The cell 
suspension was immediately transferred to a 25 cm^flask and incubated at 37°C in 
5% CO^. 
(k) Production of monoclonal antibodies in culture 
The hybridomas were cultured to a concentration of 1-2 x lOVml at 37°C and 
cells harvested. The supernatant was collected and stored at -20°C. 
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(I) Production of monoclonal antibodies in ascites 
Balb/c mice were initially primed by injecting 0.5 ml pristane. One week 
later, 5-10 x 10^ hybrid cells/mouse were injected intraperitoneally in 1 ml DMEM. 
The ascitic production can be determined by the bulging of mouse peritoneal 
cavity. This usually can be seen after 10-14 days. The ascitic fluid was drawn into 
a sterile syringe and centriftiged at 1500 rpm for 10 min. The clear ascitic fluid was 
collected. The cells, if healthy, were re-injected into pristane-primed mice. Antibody 
activity in ascitic fluid was assayed and the fluid stored at -80°C in small aliquots. 
(m) Isolation of monoclonal IgG by Protein G-Sepharose 4B 
Monoclonal IgG from ascitic fluid was isolated by affinity chromatography 
on Protein G-Sepharose 4B. One ml of ascitic fluid was diluted with 1 ml of 500 mM 
Na-phosphate buffer, pH 8.0 and applied to column (1 cm x 5 cm) equilibrated with 
the same buffer. Tlae wash-through was recycled 2-3 times and finally the column 
was washed extensively with 100 mM Na-phosphate, pH 8.0 containing 150 mM 
NaCl to remove unbound material. The bound IgG was eluted with 100 mM acetic 
acid containing 150 mM NaCl and neutralized with 1 ml 1 M Tris-HCl, pH 9.5. Four 
ml fractions were collected and read at 280 nm. The IgG was then dialized against 
PBS, pH 7.4 and stored at -20°C with 0.1% sodium azide for further use. 
(n ) I s o t y p i n g 
Isotyping of monoclonal Ig was done essentially as described for direct binding 
ELISA, except that after coating the antibody, anti-IgM and IgG subclasses were coated. 
Plate was developed using anti-Ig-HRP conjugate and ortho-phenylenediamine and 
hydrogen peroxide as substrate. 
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Band Shift Assay 
Band shift assay was performed for the visual detection of antigen-antibody 
interaction (Sanford et al., 1988). A constant amount of antigen (ROS-DNA or 
native DNA) was incubated with varying amounts of IgG in PBS, pH 7.4 for 2 hr at 
37°C and overnight at 4°C. One-tenth volume of dye solution was added to the 
mixture and electrophoresed on 0.8% agarose for 2 hr at 30 mA in TAE buffer, pH 
7.9. The gels were stained with ethidium bromide (0.5 ng/ml), visualized under UV 
light and photographed. Appropriate controls were run simultaneously. 
Enzyme Linked Immunosorbent Assay 
(a) Buffers and reagents 
Tris buffered saline (TBS) 
10 mM Tris 
150 mMNaCl, pH7.4 
Tris buffered saline-Tween 20 (TBS-T) 
20 mM Tris 
144 mM NaCl 
2.68 mM KCl, pH 7.4 containing 500 \il Tween20/1 
Carbonate-bicarbonate buffer 
15 mM sodium carbonate 
35 mM sodium bicarbonate, pH 9.6, 
containing 2 mM magnesium chloride 
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Citrate-phosphate buffer 
50 mM citric acid 
50 mM Na^HPO^, pH 5.0 
Substrates 
(i) 500 ^g p-nitro- phenyl phosphate/ml of carbonate-bicarbonate buffer 
(ii) 500 ng o-phenylene diamine (OPD)/ml citrate- phosphate buffer, containing 
1 ^1/ml of hydrogen peroxide 
(b) Procedure 
ELISA was performed essentially as described by Aotsuka et al. (1979). 
Polystyrene (96 well) microtiter plates were coated with 100 |iil of antigen (native 
and 400 bp ROS-DNA) at a concentration of 2.5 ng/ml in TBS for 2 hr at room 
temperature and overnight at 4°C. The antigen coated wells were washed three 
times with TBS-T to remove unbound antigen. Unoccupied sites were blocked with 
150 nl of 1.5% BSA in TBS for 3 hr at room temperature. BSA was added both, in 
antigen coated and control wells. The plates were washed with TBS-T and antibody 
(100 nl/well) to be tested, diluted in TBS was added to each well. After incubating 
plates for 2 hr at room temperature, the bound antibodies were assayed by an 
appropriate anti-immunoglobulin alkaline phosphatase or horse radish peroxidase 
conjugate using p-nitrophenyl phosphate or the ortho-phenylenediamine/hydrogen 
peroxide substrate respectively. The plates were incubated for 1-2 hr and reaction 
stopped in the case of ortho-phenylenediamine/hydrogen peroxide system with 50 jil 
of 5 N HjSO^ and read at 490 nm. In the case of para-nitrophenyl phosphate, the 
absorbance was read at 410 nm. Each sample was coated in duplicate. Results were 
expressed as a mean of A. — A 
'^ test control 
57 
Competition ELISA 
The antigeiaic specificity of the antibodies was determined by inhibition 
experiments (Hasan et al., 1991). Varying amounts of inhibitors (0-20 fig/ml) were 
mixed with a constant amount of antiserum or IgG. The mixture was incubated at 
room temperature for 2 hr and overnight at 4°C. The immune complex thus formed 
was coated in the wells instead of the serum. The remaining steps were the same 
as in direct binding ELISA. The results were expressed as percent inhibition. 
inhibited 
Percent inhibition = 1 - x 100 
uQiahibitd 
Isolation of DNA from Human Lymphocytes 
(a) Isolation of lymphocytes 
Blood was collected in EDTA from cancer patients and normal healthy 
individuals of different age groups. Lymphocytes were harvested by first lysing 
erythrocytes using RBC lysing solution (155 mM NH^Cl, 10 mM NaHCOj, 0.1 mM 
EDTA, pH 7.4). 
(b) Procedure 
The blood samples were cooled to 4°C and 10 volumes of RBC lysis solution 
was added, swirled for 5-10 min. The sample was centrifuged at 2000 rpmat 4°Cfor 
10 min to harvest the lymphocytes. This process was repeated 3-4 times, until a 
clear, white pellet of lymphocytes was obtained. 
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( c ) Isolation of human DNA 
Human DNA was isolated from lymphocytes essentially as described by Baas 
et al. (1984). Lymphocytes were initially lysed by lymphocyte lysis buffer (10 mM 
Tris, 2 mM EDTA, 400 mM NaCl, containing 1% SDS and 1 mg/ml proteinase K). 
(d) Procedure 
The lymphocytes were resuspended in lymphocyte lysis buffer, incubated at 
50°C for 1 hr and 37°C overnight with constant shaking. To this, was added an equal 
volume of phenol-chloroform-isoamyl alcohol (25:24:1), extracted for 15 min and 
allowed to stand for 15 min. The aqueous layer was removed carefully and the 
extraction step repeated 2 to 3 times. To the aqueous layer was added one-tenth 
volume of 3 N sodium acetate buffer, pH 5.2 and two volumes of cold absolute 
ethanol to precipitate DNA. The DNA was collected by centrifugation, washed 
once with 70% ethanol and allowed to dry. It was then dissolved in PBS, pH 7.4. 
The absorbance of DNA solution was read at 260 nmand 280 nmto ascertain its purity 
and concentration. 
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Commercially available calf thymus DNA was purified free of proteins, RNA 
and single-stranded regions and digested with micrococcal nuclease to obtain 
fragments varying from about 70-800 base pairs (bp). DNA fragments of 
approximately 400 bp size were obtained by gel filtration on Sepharose 4B column 
(46 cm X 1.2 cm) (Fig.2). The size of the DNA fragments was analyzed by PAGE 
using X DNA, Hindlll and EcoRI double digest as standard marker (Fig. 2 inset). 
Characterization of ROS-DNA 
Native and 400 bp (approximate size) calf thymus DNA were modified with 
reactive oxygen species (ROS) generated by the UV irradiation (253.7 nm) in the 
presence of hydrogen peroxide. The modified samples were dialyzed extensively 
against PB S, pH 7.4 to remove excess hydrogen peroxide. The UV spectra of ROS-
DNA revealed a marked hypochromicity at 260 nm. The corresponding controls i.e. 
DNA treated with hydrogen peroxide (without UV irradiation) or DNA treated with 
UV irradiation alone showed no appreciable change in their UV absorption 
characteristics. The spectra of native and 400 bp ROS-DNA are shown in Figs. 3 
and 4. 
Thermal Denaturation of Native and ROS-DNA 
Thermally induced transitions were measured spectrophotometrically at 
260 nm by heating nucleic acid samples at a rate of l°C/min. Melting curves were 
obtained at temperatures from 30°C to 95°C. The increase in absorbance at 260 nm 
was taken as a measure of denaturation. The process was characterized by determining 
the percent DNA in denatured state as a function of temperature and by computing 
the melting temperature (Tm). Figures 5 and 6 show the thermal denaturation 
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Fig. 2. Elution profile of micrococcal nuclease digested calf thymus DNA on 
Sepharose 4B column. 
Inset: Polyacrylamide gel electrophoresis of fractionated DNA. 
Lanes (3-11) represent alternate fractions from 22-38, while lanes 1 and 
2 contained native DNA and X D N A Hindlll and EcoRI double digest 
as marker respectively. 
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Fig. 3. UV absorption spectra of native and ROS-DNA. 
Native DNA ( ), UV irradiated DNA ( ), DNA-hydrogen 
peroxide complex ( ) and ROS-DNA ( ). 
62 
u 
c 
o 
u 
o 
Ifl 
fi 
f n 
\\ 
\\ 
\\ 
\\ 
\ \ 
\ \ 
200 300 
Wavelength(nm) 
AOO 
Fig. 4. UV abisorption spectra of 400 bp DNA and 400 bp ROS-DNA. 400 bp 
DNA ( ), UV irradiated DNA ( ) and ROS-DNA ( ). 
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Fig. 5. Thermal denaturation profile of native ( # ) and ROS-DNA ( Q ). 
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profile of native, ROS-DNA and 400 bp DNA and 400 bp ROS-DNA. Native DNA 
did not show hyperchromicity before the sharp transition between 80-90°C. The 
data is consistent with the thermal stability range of native DNA. The Tm was found 
to be 87.5°C for both nDNA and 400 bp DNA. In contrast, ROS-DNA showed a 
progressive denaturation starting from 65°C which persisted till 90°C. The Tm was 
found to be 81 °C (Fig. 5). In case of 400 bp ROS-DNA, the denaturation commenced 
from 45°C and persisted till 92°C. The Tm was found to be 73°C (Fig. 6). The results 
show a net decrease in Tm of 6.5°C and 14.5°C in ROS-DNA and 400 bp ROS-DNA 
respectively. These findings point out structural alterations in DNA and a partial 
destruction of the secondary structure of DNA on interaction with ROS. The major 
UV absorption and thermal denaturation characteristics of native and ROS-DNA 
are listed in Table 4. 
Hydroxyapatite Column Chromatography of Native and ROS-DNA 
Nucleic acids with different secondary structures have more affinity for 
hydroxyapatite than flexible, disordered polymers. To ascertain the double-
strandedness of ROS-DNA, native and modified DNA samples were fractionated 
on hydroxyapatite column. 
Calf thymus DNA samples (ROS-modified and unmodified) in 10 mM sodium 
phosphate buffer, pH 6.8, were applied to hydroxyapatite column, equilibrated 
with the same buffer. After washing the unbound material, batch elution was 
carried out with 125 mM and 250 mM Na-K phosphate buffer, pH 6.8. Three ml 
fractions were collected and absorbance monitored at 260 nm and elution profile 
was plotted. Native DNA eluted as a single peak at 250 mM Na-K phosphate buffer, 
pH 6.8 (Fig. 7a). The elution profile of ROS-DNA showed a minor peak (20% of 
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TABLE 4 
UV Absorption and Thermal Denaturation Characteristics of 
Native and ROS-DNA 
Parameter Native DNA ROS-DNA 400 bp 400 bp 
native ROS-DNA 
DNA 
Absorbance ratio 2.14 2.05 1.8 1.9 
Hyperchromicity 35.4 21.2 20.7 13.7 
at95°C,(%) 
Melting temperature 87.5 81.0 87.5 73.0 
(Tm),°C 
Onset of duplex 84.0 65.0 83.0 50.0 
melting 
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Fig. 7. HydroKyapatite column chromatography of native DNA (a) and ROS-
DNA (b). Batch elution was carried out with 125 mM and 250 mM 
sodium potassium phosphate buffer, pH 6.8. 
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total ROS-DNA applied) eluting with 125 mM buffer, while a major fraction eluted 
with 250 mM buffer (Fig. 7b), accompanied by a shift in the peak position. A similar 
elution profile was obtained for unmodified and ROS-modified 400 bp DNA 
(Fig. 8a,b). The minor fraction may be attributed to the generation of single-strand 
breaks and the shift in peak position to weaker interactions with the matrix as a 
consequence of local perturbations in the secondary structure of DNA. 
Nuclease SI Digestibility of ROS-DNA 
ROS-modified and unmodified native and 400 bp DNA were digested with 
nuclease SI (20 units/^ig DNA) and resolved by agarose gel electrophoresis. The 
controls were the unmodified DNA samples, with and without nuclease S1 treatment. 
Figure 9 shows the nuclease SI digestibility of native and ROS-DNA. Nuclease SI 
treated ROS-DNA showed total digestion after 30 min of incubation, while nDNA 
remained undigested. 400 bp ROS-DNA too showed a similar electrophoretic 
profile, except that a faint band was still visible after 30 min of incubation with 
nuclease SI, compared to the untreated control (Fig. 10). Native 400 bp DNA 
remained undigested. Hydrogen peroxide in the presence of UV light therefore 
created sufficient structural alterations in DNA to be a substrate for single strand 
specific nuclease SI. 
Alkaline Sucrose Density Gradient Ultracentrifugation 
The ROS-modified DNA samples were subjected to sucrose density gradient 
ultracentrifugation under alkaline conditions to detect single strand breaks. Nucleic 
acid samples were denatured by the addition of 0.2 N NaOH, layered on top of a 
5-20% linear alkaline sucrose gradient and centrifuged at 30,000 rpm for 1 hr. The 
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Fig.8 . Hydroxyapatite column chromatography of 400 bp native DNA (a) and 
400 bp ROS-DNA (b). Batch elution was carried out with 125 mM and 
250 mM sodium potassium phosphate buffer, pH 6.8. 
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1 2 3 ^ 
Fig. 9. Nuclease SI digestibility of native and ROS-DNA. Lane 1 contained 
native DNA, while lane 2 contained nDNA treated with nuclease SI. 
Lane 3 contained ROS-DNA, while lane 4 contained ROS-DNA treated 
with nuclease SI for 30 min. Electrophoresis was carried out on 0.8% 
agarose for 2 hr at 30 mA. 
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Fig. 10. Nuclease SI digestibility of 400 bp unmodified and 400 bp ROS-DNA. 
Lane 1 contained 400 bp native DNA, while lane 2 contained 400 bp 
DNA treated with nuclease SI. Lane 3 contained 400 bp ROS-DNA, 
while lanes 4 and 5 contained ROS-DNA treated with nuclease SI for 
15 and 30 min respectively. Electrophoresis was carried out on 0.8% 
agarose for 2 hr at 30 mA. 
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bottom of the tubes were pierced, fractions collected, monitored at 260 nm and data 
plotted as absorbance at 260 nm against fraction number. Figure 11 shows the 
sedimentation profile of native and ROS-DNA. Native DNA banded as a sharp, 
symmetrical peak. In contrast, ROS-DNA showed a diffused sedimentation profile 
indicating the generation of single strand breaks. The ROS-modified DNA contained 
majority of low molecular weight species and therefore the diffused pattern in 
sedimentation. Similar results were obtained for 400 bp unmodified and modified 
DNA (Fig. 12). 
Modification of Nitrogenous Bases in DNA by ROS 
In order to separate and quantify the modification of bases, ROS-DNA 
solutions were subjected to acid hydrolysis. The neutralized hydrolyzate was 
applied to a DEAE Sephadex A-25 column and eluted with a linear gradient of 
1-20 mM Tris-HCl, pH 7.6. The elution profile of individual standard bases is 
shown in Figure 13. The elution profile of native or unmodified DNA was similar 
to that obtained with individual bases (Fig. 14). 
Figure 15 shows the elution profile of acid hydrolyzate of ROS-DNA. The 
peaks obtained were identified by comparing with the chromatographic pattern of 
the standard bases. The first and second peaks represent modified and unmodified 
cytosine, while the third and fourth peaks represent modified and unmodified 
thymine. Adenine also eluted as two peaks (numbers 5 and 6) as also guanine 
(numbers 7 and 8) representing the modified and unmodified base. The extent of 
modification of bases by ROS was determined by measuring the peak areas of the 
modified and the corresponding unmodified bases. Among the bases modified, 
thymine was modified to the maximum extent of 46.8%, while cytosine, guanine 
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Fig. 11. Alkaline sucrose density gradient ultracentrifugation of native ( Q ) 
and ROS-DNA ( 0 ). Samples of DNA were layered on sucrose 
gradient (5-20%) and centrifuged at 30,000 rpm for 1 hr. The bottom of 
the tube was pierced, 0.5 ml fractions collected and absorbance read at 
260 nm. 
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Fig. 12. Alkaline sucrose density gradient ultracentrifugation of 400 bp DNA 
( O ) and ROS-DNA ( # ). The experiment was performed as described 
in legend to Fig. 11. 
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Fig. 13. Elution profile of standard individual DNA bases on DEAE-Sephadex 
A-25 column. Cytosine (a), thymine (b), adenine (c) and guanine (d). 
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Fig. 14. Fractionation of acid hydrolyzed native DNA on DEAE-Sephadex A-25 
column. Peaks 1, 2, 3 and 4 represent cytosine, thymine, adenine and 
guanine respectively. 
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Fig. 15. Elution profile of bases from acid hydrolyzed ROS-DNA on DEAE-
Sephadex A-25 column. Peaks 1 and 2 represent modified and unmodified 
cytosine, peaks 3 and 4 represent modified and unmodified thymine, 
peaks 5 and 6 represent modified and unmodified adenine, peaks 7 and 
8 represent modified and unmodified guanine. 
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and adenine were modified to the extent of 19.8%, 30.6% and 16.7% respectively 
(Table 5). 
A similar elution profile of modified and unmodified bases was obtained with 
the acid hydrolyzate of 400 bp ROS-DNA (Fig. 16). In this case too, thymine was 
modified to an extent of 58%, while cytosine and guanine were modified to an 
extent of 15.6% and 20% respectively (Table 5). Adenine eluted as a single peak 
and was not modified. 
Antigenicity of Native ROS-DNA 
Antibodies against native ROS-DNA were raised in goats. The antigenic 
specificity of the induced antibodies was assayed by direct binding and inhibition 
ELISA. The binding of these antibodies to the immunogen and native DNA was 
probed by band shift assay. 
(a) Evaluation of antibody response 
Direct binding ELISA was used to characterize the immune response in goat 
following immunization with ROS-DNA. The serum showed a high titre of greater 
than 1:12800 (Fig. 17).Pre-immune serum served as negative control and did not 
show any appreciable binding to modified DNA. 
(b) Purification and characterization of immune IgG 
Immune IgG was isolated from serum by DEAE Sephacel column 
chromatography of 35% saturated ammonium sulphate precipitated y-globulin 
fraction (Fig. 18). The isolated IgG was further affinity purified on a ROS-DNA-
poly-lysyl-Sepharose 4B column (Fig. 19). The purity of the IgG was ascertained 
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TABLE 5 
Level of Modification of DNA Bases in Native and 400 bp 
DNA Modified with Reactive Oxygen Species 
Base Percent modification 
ROS-DNA 400 bp ROS-DNA 
Adenine 16.7 
Guanine 30.6 20.0 
Cytosine 19.8 15.6 
Thymine 46.8 58.3 
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Fig. 16. Elution profile of bases fi-om acid hydrolyzed 400 bp ROS-DNA on 
DEAE- Sephadex A-25 column. Peaks 1 and 2 represent modified and 
unmodified cytosine, peaks 3 and 4 represent modified and unmodified 
thymine, peak 5 represents unmodified adenine, while peaks 6 and 7 
represent modified and unmodified guanine. 
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Fig. 17. Binding ofimmune( # ) and pre-immune ( O )goat serum antibodies 
to ROS-DNA. 
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Fig. 18. Elution profile of anti-ROS-DNA IgG from 3 5% saturated ammonium 
sulphate precipitated immune serum on DEAE- Sephacel column. Elution 
was carried out with a linear gradient of 10 mM to 300 mM sodium 
phosphate buffer, pH 8. 
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Fig. 19. Elution profile of affinity purified anti-ROS-DNA IgG from ROS-DNA-
poly-lysyl-Sepharose 4B affinity column with a linear gradient of 0.15 
M to 3.0 M sodium chloride in 10 mM sodium phosphate buffer, pH 7.4. 
Inset: SDS-PAGE of affinity purified IgG on 7.5% acrylamide gel. 
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by SDS-PAGE under non-reducing conditions (Fig. 19 inset) with the IgG moving 
as a single band. 
Direct binding ELISA of the purified IgG showed strong reactivity with the 
immunogen (Fig. 20). Pre-immune IgG as negative control showed negligible 
binding to ROS-DNA. 
(c) Antigenic specificity of anti-ROS-DNA antibodies 
The antigenic specificity of the induced anti-ROS-DNA antibodies was 
characterized by competitive inhibition assays using the immunogen, nucleic 
acids, synthetic polynucleotides and bases as inhibitors. A maximum of 89% 
inhibition of antibody binding to solid phase bound antigen was observed with the 
immunogen as inhibitor (Fig. 21). The induced antibodies were highly specific for 
ROS-DNA with only 4 ng/ml inhibitor required to inhibit 50'% antibody activity 
(Table 6). The induced antibodies showed a broad spectrum of reactivity as 
observed by its binding to a variety of nucleic acid antigens. Competition assays 
with native DNA showed a considerable inhibition of antibody activity of 74% 
(Fig. 21). Fifty percent inhibition was achieved with 6.4 ng/ml of native DNA. 
Single-stranded DNA showed a maximum of 80% inhibition with 7.2 ^ig/ml required 
to attain 50% inhibition in antibody binding to the solid phase antigen (Table 6). 
Total RNA from buffalo thymus and brominated DNA (brominated in 4 M NaCl) 
showed moderate inhibitions of 41% (Fig. 21). 
Adenine, thymine and their ROS-modified forms were used as inhibitors of 
antibody activity. Adenine, ROS-adenine and thymine were non-inhibitory showing 
inhibitions of 25%, 18% and 24% respectively (Fig. 22a). In contrast, ROS-thymine 
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Fig. 20. Binding of immunoaffinity purified anti-ROS-DNA IgG ( 
immune IgG { Q ) to ROS-DNA. 
) and pre-
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Inhibition of anti-ROS-DNAIgG binding to ROS-DNA. The competitors 
were ROS-DNA ( Q ), nDNA ( # ), RNA {A ) and Br-DNA 
( A ). 
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was a potent inhibitor, showing a maximum inhibition of 53%(Fig. 22a). The amount 
of ROS-thymine required for 50% inhibition in antibody activity was 12 ^ig/ml 
(Table 6). Among the homopolymers, poly(dA) showed negligible inhibition of 
25%, while ROS-poly(dA) was inhibitory to the extent of 45% (Fig. 22b). Poly(dT) 
was also moderately inhibitory and showed an inhibition of 40% in antibody 
activity, while ROS-poly(dT) was inhibitory to an extent of 59% (Fig. 22b). The 
concentration ofROS-poly(dT) required for 50% inhibition was 9.5 ng/ml. Poly(dG) 
showed moderate inhibition of 34%, while poly(dG).poly(dC), poly(dA-
dC).poly(dG-dT) and poly(dG-dC).poly(dG-dC) showed maximum inhibitions of 
55%, 51% and 48.5% respectively (Fig. 22a,b).Poly(dI-dC).poly(dI-dC) and 
poly(rG).poly(dC) were poor inhibitors of antibody activity (Table 6). Fifty percent 
inhibition of antibody binding to antigen was achieved with 20 |ig/ml of poly(dA-
dC).poly(dG-dT) and 13 ng/ml of poly(dG).poly(dC). Table 6 shows a summary of 
the data on the binding characteristics of anti-ROS-DNA goat IgG as determined by 
inhibition ELISA. Their relative affinities have also been computed. 
Band shift assay 
The binding of the anti-ROS-DNA IgG to ROS-DNA and native DNA was 
further ascertained by band shift assay (Fig. 23). Constant amounts of ROS- and 
native DNA were incubated with varying amounts of immune IgG for 2 hr at room 
temperature and overnight at 4°C. The immune complexes were then electrophoresed 
on 0.8% agarose for 2 hr at 30 mA. Figure 23a shows the binding of IgG to ROS-
DNA. As clearly evident, with an increase in the amount of IgG, there was an 
increase in the formation of high molecular weight immune complexes, which 
resulted in retarded mobility. The recognition of native DNA by anti-ROS-DNA 
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Fig. 22. Inhibition of anti-ROS-DNA IgGbinding to ROS-DNA. The competitors 
were (a) adenine ( Q ), ROS-adenine ( 0 ), thymine ( A ), ROS-
thymine ( # ), poly(dG) ( A ), poly(dG).poly(dC) ( © ) and 
(b) poly(dA) ( O ), ROS-poly(dA) ( A ), poly(dT) ( • ), ROS-poly(dT) 
( © ), poly(dA-dC).poIy(dG-dT) ( O ), poly(dG-dC).poly(dG-dC) 
( A ). 
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TABLE 6 
Antigenic Specificity of Anti-ROS-DNA Antibodies 
Competi tor M 
ROS-DNA 
Native DNA 
ss-DNA 
Br-DNA 
RNA 
Adenine 
ROS-adenine 
Thymine 
ROS-thymine 
Poly(dA) 
ROS-poly(dA) 
Poly(dT) 
ROS-poly(dT) 
Poly(dG) 
Poly(dG-dC).poly(dG-dC) 
Poly(dA-dC).poly(dG-dT) 
Poly(dG).poly(dC) 
Poly(dI-dC).poly(dI-dC) 
Poly(rG).poly(dC) 
aximum percent 
inhibition at 
20 fig/ml 
89.2 
73.8 
80.1 
41.4 
41.4 
24.8 
18.1 
24.0 
53.2 
24.9 
45.0 
39.9 
58.9 
33.8 
48.5 
51.1 
55.2 
30.6 
22.1 
Concentration 
for 50% 
inhibition 
(fig/ml) 
4.0 
6.4 
7.2 
-
-
-
-
-
12.0 
-
-
-
9.5 
-
-
20.0 
13.0 
-
-
Percent 
relative 
affinity 
100.0 
62.5 
55.6 
-
-
-
-
-
33.3 
-
-
-
42.1 
-
-
20.0 
30.8 
-
-
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(.a) (b) 
Fig. 23. Band shift assay of anti-ROS-DNA IgG binding to ROS-DNA and 
native DNA. (a) ROS-DNA (1 \ig) was incubated with 20, 40, 60 and 80 ng 
IgG (lanes 2-5) for 2 hr at 37°C and overnight at 4°C. Lane 1 contained 
ROS-DNA. (b) Native DNA (0.5 ng) was incubated with 25, 50, 75 and 
100 ng IgG (lanes 2-5) for 2 hr at 37 °C and overnight at 4°C. Lane 1 
contained native DNA. Electrophoresis was performed on 0.8% agarose 
for 2 hr at 30 mA. 
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IgG was reiterated by the shift in electrophoretic mobility upon immune complex 
formation (Fig. 23b). 
Production of Monoclonal Antibodies Against 400 bp ROS-DNA 
Monoclonal antibodies were generated against fractionated ROS-DNA 
(approximate size 400 bp). Balb/c mice were immunized with 400 bp ROS-DNA. 
The anti-ROS-DNA antibody response in mice was screened by direct binding 
ELISA. The response in five different mice after one booster dose of antigen was 
moderate to good (Fig. 24). A second booster led to all mice showing a good 
response against ROS-DNA (Fig. 25). Mouse #2 died as a result of infection, while 
in #4 and #5, fusion was unsuccessful. 
(a) Fusion of spleen cells with Sp2/0 
The best responder was sacrificed and spleen cells were fused with the 
myeloma cell Sp2/0. Ten days after the fusion, the plates were screened for anti-
ROS-DNA antibody in the culture supernatants. Only one well showed a good 
antibody activity (P^B^), while three more showed a weak response (Fig. 26). 
(b) Cloning and propagation of antibody-producing hybridomas 
The hybridomas of P^B ,^ P^B^ and P^A^ were cloned in duplicates and the 
remaining cells frozen in liquid nitrogen. After 10-14 days, the cloned hybrids 
were screened. Among these three cloned hybridomas, only clones of P^B^ showed 
antibody activity against the immunogen (Fig. 27). Eight positive clones were 
obtained, which were expanded, cloned and some cells were frozen. 
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Fig. 24. Immune response ofBalb/c mice to 400 bpROS-DNA after 1st boo ster. 
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Fig. 26. Screening of culture supernates to assay anti-ROS-DNA antibody 
activity. 
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Fig. 27. Screening the clones of P^ B^ for anti-ROS-DNA antibody activity. 
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Twelve to fourteen days after the second cloning, the plates were screened 
for antibody activity. A large number of positive clones were obtained (9 in 
number), while many more were weakly positive (Fig. 28). The positive clones 
were expanded in culture flasks for ascites production and frozen. The positive 
clones, PjCjjD^, PjC^E^ and P^Bj^H, were injected intraperitoneally into pristane-
primed mice (1x10* cells/mouse) for propagation in ascites. One week later, the 
ascitic fluid was tapped. The ascitic fluid was centrifuged to separate the hybridoma 
cells and the fluid frozen for subsequent use. 
(c) Isotyping of Monoclonal Antibody 
Isotyping of the monoclonal antibody was performed to determine its sub-
class. The study showed the clones to be of IgGl subclass (Table 7). 
(d) Purification of Monoclonal Antibodies 
Monoclonal IgG were purified from ascitic fluid of the three clones P,CjjD^, 
PjC^Ej and PjBjjH^ by affinity chromatography on Protein G-Sepharose 4B column. 
Figure 29 shows the elution profile of IgG obtained from P^C j^D^ on Protein G-
Sepharose column. The purity of the isolated IgG was ascertained by SDS-PAGE 
under non-denaturing conditions which resulted in a single band (Fig. 29 inset). 
(e) Characterization of Monoclonal Antibody 
Direct binding ELISA was performed to determine the binding of monoclonal 
IgG to the antigen. Among the three clones, only P^C j^D^ and PjC^E^ showed a 
concentration dependent binding to the solid phase antigen (400 bp ROS-DNA) 
(Fig. 30 and 31). Competition inhibition experiments showed strong binding of 
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Fig. 28. Screening of recloned hybridomas to evaluate anti-ROS-DNA 
monoclonal antibody activity. 
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TABLE 7 
Isotyping of Monoclonal Antibodies 
Clone 
P3C„D, 
P3H.F, 
P.C.E, 
Isotype 
IgGl 
IgGl 
IgGl 
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Fig. 29. Elution profile of anti-ROS-DNA monodonaJ IgG from done P C D 
on Protein G-Sepharose 4B affinity column. 
Inset: SDS-PAGE of purified IgG on 7.5% acrylamide gel. 
100 
E 
c 
o 
9> 
U 
C 
o 
n 
c 
O 
(A 
JO 
< 
IgG Concentrotion (AJg/m() 
Fig. 30. Binding of monoclonal antibody (clone PjCjjD^) ( 
IgG ( O ) to 400 bp ROS-DNA. 
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Fig. 3 1 . Binding of monoclonal antibody (clone PjC^E^) ( Q ) and pre-immune 
IgG ( • ) to 400 bp ROS-DNA. 
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monoclonal antibody (PjCjjD^) with the immunogen, showing a maximum inhibition 
of 76.5% (Fig. 32). The antibody showed high specificity for the immunogen as 
only 4.4 ^g/ml of inhibitor (400 bp ROS-DNA) was required to effect 50% 
inhibition in antibody binding to the antigen (Table 8). P,C^E^ showed no inhibitory 
activity with the immunogen and was not used for further studies. 
(f) Fine Antigenic Specificity of Monoclonal IgG 
To characterize the fine antigenic specificity of the monoclonal antibody, 
competition-inhibition assay was performed. When ROS-DNA was used as an 
inhibitor, a maximum of 84% in antibody binding to the antigen was obtained 
(Fig. 32). The concentration of native ROS-DNA required to inhibit 50% antibody 
activity was 3.0 ^ig/ml. 200 bp ROS-DNA as inhibitor showed a maximum inhibition 
of 60% (Fig. 32) with 10 ng/ml required for 50% inhibition in antibody activity. The 
monoclonal antibody showed some degree of cross-reactivity by its recognition of 
native DNA. A maximum inhibition of 65% was achieved when native DNA was 
used as inhibitor and 11 ng/ml was required for 50% inhibition in antibody activity. 
The specificity of the monoclonal antibody was also assayed using nitrogenous 
bases, deoxyribonucleotide homopolymers and their ROS-modified forms. The 
deoxyribonucleotide homopolymer poly(dG) was a moderate inhibitor causing only 
33% inhibition (Table 8). The ribonucleotide polymer poly(G) and ROS-poly(G) 
were also used as inhibitors. Poly(G) showed negligible inhibition of 27%, while 
ROS-poly(G) was an effective inhibitor of antibody binding to antigen to an extent 
of 47% (Fig. 33). Guanine showed negligible inhibition of IgG activity (Fig. 33) 
whereas, ROS-guanine showed a maximum inhibition of about 48% (Fig. 33). 
ROS-modified thymine was an effective inhibitor showing a maximum inhibition of 
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Fig. 32. 
0.1 1.0 10.0 
Inhibitor Conctntrotion (pQiml) 
100 
Inhibition of anti-ROS-DNA monoclonal antibody (P^C D )^ binding to 
400 bp ROS-DNA. The competitors were ROS-DNA ( O ), 400 bp ROS-
DNA ( # ), 200 bp ROS-DNA ( A ) and nDNA ( Q )• Microtitre 
plates were coated with 400 bp ROS-DNA (2.5 pg/ml). 
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TABLE 8 
Inhibition of Anti-ROS-DNA Monoclonal Antibody Binding 
to ROS-DNA by a Variety of Nucleic Acid Polymers 
Inhibitors Maximum percent Concentration for Percent relative 
inhibition at 50% inhibition affinity 
20 fig/ml (^g/ml) 
400 bp ROS-DNA 
ROS-DNA 
200 bp ROS-DNA 
Native DNA 
Thymine 
ROS-thymine 
Po]y(dT) 
ROS-poly(dT) 
Thymidine 
ROS-thymidine 
Guanine 
ROS-guanine 
Cytosine 
ROS-cytosine 
Poly(dA) 
ROS-poly(dA) 
Poly(G) 
ROS-poly(G) 
Poly(dG) 
76.5 
84.0 
59.7 
65.1 
31.9 
66.5 
34.8 
68.2 
27.3 
57.2 
27.3 
46.8 
19.8 
24.2 
-
-
27.0 
47.2 
32.9 
4.4 
3.0 
10.0 
11.0 
100.0 
146.6 
44.0 
40.0 
9.0 48.8 
3.6 122.2 
9.0 48.8 
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Fig. 33. Inhibition of anti-ROS-DNA monoclonal antibody (PjCjjDj) binding to 
400 bp ROS-DNA. The competitors were guanine ( A ), ROS-guanine 
( • ), poly(G)( O ) and ROS-poly(G) ( # ). 
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66.5% (Fig. 34a). The concentration of ROS-thymine required to inhibit 50% of 
antibody activity was 9 ng/ml. ROS-thymidine was also an effective inhibitor with 
57% being the maximum inhibition caused (Fig. 34a) and 9 ng/ml was required for 
50% inhibition. ROS-poly(dT) was an effective inhibitor of monoclonal antibody 
binding to ROS-DNA. It showed a maximum inhibition of 68% and only 3.6 ng/ml 
of inhibitor was required to achieve 50% inhibition (Fig. 34a). In contrast to the 
inhibitory activity of ROS-thymine, ROS-thymidine and ROS-poly(dT), their 
unmodified forms showed low levels of inhibition of antibody activity. Thymine 
showed a maximum inhibition of 32%, thymidine 27% and poly(dT) 34.8% 
(Fig. 34b).Cytosine, ROS-cytosine, poly(dA) and ROS-poly(dA) were not effective 
inhibitors and showed negligible inhibitory activity (Table 8). Table 8 gives the 
summarized data on the inhibitory capacity of native ajid modified nucleic acids to 
anti-ROS-DNA monoclonal antibody along with their relative affinity for the 
antibody. 
Band Shift Assay 
Band shift assay was performed for the visual detection of antigen-antibody 
interaction. Constant amounts of antigen (400 bp ROS-DNA) was incubated with 
varying amounts of monoclonal IgG for 2 hr at 37°C and overnight at 4°C. The 
immune complexes were then electrophoresed on 0.8% agarose for 2 hr at 30 mA. 
Figure 35 shows the binding of the monoclonal IgG to 400 bp ROS-DNA. As clearly 
evident, an increase in the amount of IgG led to an increase in the formation of high 
molecular weight immune complexes, resulting in retarded mobility. The band shift 
assay clearly reiterates the direct-binding and competition ELISA data. 
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Fig. 34. 
0.1 1.0 10.0 
Inhibitor Conc*ntrotion (>jg/ml) 
Inhibition of anti-ROS-DNA monoclonal antibody (PjC,,D^) 
binding to 400 bp ROS-DNA. Tbe competitors were (a) ROS-thymine 
( ),ROS-thymidine ( A ), ROS-poly(dT) (A ) and (b) poly(dT) 
( O )> thymidine ( ), thymine ( A ). 
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Fig. 35. Band shift assay of anti-ROS-DNA monoclonal IgG binding to 400 bp 
ROS-DNA. Lane 1 contained 3 jig ROS-DNA, while lanes 2-5 contained 
3 ng ROS-DNA incubated with 25, 50, 75 and 1 GO ng IgG for 2 hr at 37 
°C and overnight at 4°C. Immune complexes were electrophoresed on 
0.8% agarose for 2 hr at 30 mA. 
109 
Detection of Antibodies Reactive to Native and ROS-DNA in 
Human Sera 
Sera were collected from normal, healthy humans with no apparent disease. 
The sera were classified into four age groups - (a) below 35 years (b) 35-49 years 
(c) 50-59 years and (d) above 60 years. The population above 60 years was taken 
as the aged population, with the group 50-59 years as moderately aged. The other 
two groups served as controls. 
(a) Age group below 35 years 
Competition ELISA was performed to detect the presence of antibodies 
reactive with native and ROS-DNA. Microtitre plates were coated with ROS-DNA 
(2.5 ^ig/ml) as antigen. Six sera (four female and two male) were studied in this 
group. Only two sera showed inhibitions of 30% and 37% with nDNA (Fig. 36a), 
whereas inhibition with ROS-DNA was 30% and 33% respectively (Fig. 36b). 
These results show non-reactivity of normal human sera towards native and ROS-
DNA (Table 9). 
(b) Age group between 35-49 years 
This age group too consisted of six sera (three female and three male). 
Competition ELISA with native and ROS-DNA showed no appreciable reactivity 
with both forms of nucleic acids (Fig. 37a,b). Only one serum showed a higher 
binding towards nDNA and ROS-DNA. 
(c) Age group between 50-59 years 
Sera from nine individuals were studied in this group (six female and three 
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Fig. 36. Evaluation of the presence of antibodies against nDNA and ROS-DNA 
in the sera of normal human subjects (<35 years of age). The microtitre 
plates were coated with ROS-DNA (2.5 \ig/ml) and the competitors 
were nDNA (a) and ROS-DNA (b). The curves ( O ) . ( • ) , ( A ), 
( • ) , ( (^ ), ( O ) represent sera from different individuals. 
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TABLE 9 
Antibodies Against Native DNA and ROS-DNA in the Sera of 
Normal Healthy Individuals 
Age group No. of sera No. of sera Sera positive Sera positive Sera positive 
(Years) tested positive'' for ROS-DNA fornDNA for both 
<35 
35-49 
50-59 
>60 
6 
6 
9 
10 
-
-
1 
6 
-
-
1 
1 
'Inhibitions >45% were considered positive 
''Inhibition greater with ROS-DNA in four samples and one with nDNA 
Microtitre plates were coated with ROS-DNA (2.5 ^g/ml). The inhibitors were nDNA and 
ROS-DNA. 
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Fig. 37. Evaluation of the presence of antibodies against nDNA and ROS-DNA 
in the sera of normal human subjects (35-49 years of age). The 
micTotitre plates were coated with ROS-DNA (2.5 ^g/ml) and the 
competitors were nDNA (a) and ROS-DNA (b). The curves ( O )' 
( # ), ( A ), ( A ), ( 3 ), ( O ) represent sera from different 
individuals. 
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male). Competition ELISA with nDNA showed an inhibition in antibody activity in 
one serum by 43% (Fig. 38a), while its reactivity with ROS-DNA was lower (37%) 
(Fig. 38b). Three sera showed greater recognition of ROS-DNA for inhibitions of 
44%, 43% and 47% respectively (Fig. 39b), with lowered inhibitions in the case of 
nDNA (Fig. 39a). The rest of the sera showed negligible inhibitions with native and 
ROS-DNA. 
(d) Age group above 60 years 
Competition-inhibition ELISA of aged sera with native and ROS-DNA was 
performed with 10 sera (four female and six male). Four sera showed a higher 
recognition of both native and ROS-DNA (Figs. 40a,b and 41a,b). One serum 
showed an inhibition of 60% with ROS-DNA, while the inhibition was 53% with 
nDNA (Fig. 41a,b). Similarly, with the other three sera, the reactivity was >60%for 
ROS-DNA, compared with nDNA (55-60%) (Fig. 40a,b). One serum showed a 
moderate reactivity towards ROS-DNA (Fig. 41b), while another showed greater 
binding to nDNA (51%) than ROS-DNA (46%) (Fig. 41a,b). Four sera showed 
negligible recognition of both forms of DNA (Fig. 40 and 41). Overall, about 50% 
of the sera tested were positive for native and ROS-DNA, while one showed 
greater preference for ROS-DNA (Table 9). The results clearly demonstrate an 
increase in anti-DNA antibody levels in the aged persons, with a higher recognition 
of oxidatively damaged DNA. 
Probing Oxidative DNA Damage in Aging Population using 
Monoclonal Antibody 
Genomic DNA was isolated from lymphocytes of normal, healthy individuals 
of varying age groups. The purity and concentration of the DNA preparations were 
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Fig. 38. Evaluation of the presence of antibodies against nDNA and ROS-DNA 
in the sera of normal human subjects (50-59 years of age). The 
microtitre plates were coated with ROS-DNA (2.5 ^g/ml) and the 
competitors were nDNA (a) and ROS-DNA (b). The curves ( O )» 
( # ) , ( A ) , ( A ) , ( 3 ) represent sera firoim different individuals. 
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Fig. 39. Evaluation of the presence of antibodies against nDNA and ROS-DNA 
in the sera of normal human subjects (50-59 years of age). The 
microtitre plates were coated with ROS-DNA (2.5 \igfml) and the 
competitors were nDNA (a) and ROS-DNA (b).The curves( O ), ( ), 
( A ), ( A ) represent sera from difTerent individuals. 
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Fig. 40. Evaluation of the presence of antibodies against nDNA and ROS-DNA 
in the sera of normal human subjects (>60 years of age). The microtitre 
plates were coated with ROS-DNA (2.5 (ig/ml) and the competitors 
were nDNA (a) and ROS-DNA (b).The curves ( O ) > ( • ) , ( A ), 
( A ), ( d ) represent sera from different individuals. 
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Fig. 41. Evaluation of the presence of antibodies against nDNA and ROS-DNA 
in the sera of normal human subjects (>60 years oiT age). The microtitre 
plates were coated with ROS-DNA (2.5 ^g/ml) and the competitors 
were nDNA (a) and ROS-DNA (b).The curves ( O ) , ( • ) , ( A ), 
( • ), ( 9 ) represent sera from different individuals. 
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ascertained by A,^ „ and A,_. measurements. The isolated DNA were found to be 
pure and had 260/280 ratio of 1.78-1.92. Oxidative damage to the human genome 
was immunochemically detected using the monoclonal anti-ROS-DNA antibody as 
a probe by competition ELISA. Immune complexes were made between isolated 
DNA and monoclonal antibody. Microtitre plates were coated with 400 bp ROS-
DNA. 
(a) Age group below 35 years 
DNA was isolated from eight (four female and four male) subjects. None of 
the samples showed any inhibition of antibody activity by competition ELISA 
(Fig. 42a,b). Only two DNA samples showed a moderate inhibition of 25% and 29%, 
while one showed slightly higher inhibition (35%) (Fig. 42b). The results indicate 
a general non-reactivity of monoclonal antibody against ROS-DNA towards normal 
DNA isolated from young population. 
(b) Age group between 35-49 years 
This age group also consisted of eight samples (four female and four male). 
Three of the eight samples showed a slightly high recognition of monoclonal 
antibody. These three samples showed inhibitions of 39%, 35% and 34% 
(Figs. 43a,b), while one sample showed lower inhibition of 28% (Fig. 43b). The 
other DNA isolates were non-inhibitory. 
(c) Age group between 50-59 years 
This age group population consisted of nine samples (six female and three 
male). Only one DNA sample showed a positive inhibition of monoclonal antibody 
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Fig. 42. 
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Inhibition of anti-ROS-DNA monoclonal antibody binding to 400 bp 
ROS-DNA by DNA isolated from lymphocytes of normal, healthy 
individuals (<35 years). The microtitre plates were coated with 400 bp 
ROS-DNA (2.5 ng/ml). (a) The curves ( O ), ( • ), ( A ), ( A ) 
and (b) ( O ) , ( # ) , ( A ) , ( A ) represent DNA samples from 
different individuals. 
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Fig. 43. 
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Inhibition of anti-ROS-DNA monoclonal antibody binding to 400 bp 
ROS-DNA by DNA isolated from lymphocytes of normal, healthy 
individuals (35-49 years), (a) The curves ( O ). ( • ). 
( A ), ( A ) and (b) ( O ), ( • ), ( A ), ( A ) represent DNA 
samples from different individuals. 
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Dinamg oi 3 r/o ^rig. ^^a;. rour samples showed moderate inhibitions in the range 
of 39-42% (Figs. 44a,b). The remaining four samples were non-inhibitory. Eleven 
percent of the total sampling population was positive, while 45% were negative. 
(d) Age group above 60 years 
In this age group, the sample size was eleven (four female and seven male). 
Samples from four subjects showed a high inhibition in antibody binding. These 
samples gave maximum inhibitions of 64%, 49%, 53% and 70% (Figs. 45a,b). This 
figure constitutes 36% of the total sampled population. Two samples were moderately 
inhibitory and showed maximum inhibitions of about 37% and 39%.The remaining 
five samples did not show any appreciable inhibition of antibody binding. The 
binding data of the DNA samples with the anti-ROS-DNA monoclonal antibody is 
summarized in Table 10. 
Detection of Antibodies Reactive to Native and ROS-DNA in 
Cancer Sera 
The study comprised of 39 samples of sera from patients suffering from 
cancer of different organs/organ systems. Sera from normal, healthy individuals 
served as controls (Figs. 36, 37). Cancer sera were obtained after careful clinical 
examination of patients with proven histopathological diagnosis attending J.N. 
Medical College Hospital, A.M.U., Aligarh. 
The reactivity of serum antibodies to native and ROS-DNA was studied by 
competition ELISA. The sample contained eight sera of breast cancer. Out of these, 
six were found to be reactive towards native and ROS-DNA. Out of these six, five 
were positively recognizing ROS-DNA to a greater extent than nDNA. The maximum 
122 
0.01 
Fig. 44. 
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Inhibition of anti-ROS-DNA monoclonal antibody binding to 400 bp 
ROS-DNA by DNA isolated from lymphocytes of normal, healthy 
individuals (50-59 years), (a) The curves ( O ) , ( • ) , ( A ), 
( A ), ( » ) and (b) ( O ), ( • ), ( A ), ( A ) represent DNA 
samples from different individuals. 
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Fig. 45. Inhibition of anti-ROS-DNA monoclonal antibody binding to 400 bp 
ROS-DNA by DNA isolated from lymphocytes of normal, healthy aged 
individuals (>60 years). The microtitre plates were coated with 400 bp 
ROS-DNA (2.5 ^g/ml). (a) The curves ( Q ), ( • ), ( A ), ( A ), 
( » ) and (b) ( O ), ( ), ( A ), ( A ), ( O ), ( 3 ) represent 
DNA samples from different individuals. 
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TABLE 10 
Binding of Anti-ROS-DNA Monoclonal Antibody to DNA Isolated 
from Lymphocytes of Various Age Groups 
Age group Number of Number of samples Percent positive 
(Years) samples positive" 
<35 8 - -
35-49 8 
50-59 9 1 " 11.1 
>60 11 4 36.0 
'Inhibitions >45% were considered positive 
The microtitre plates were coated vs^ ith 400 bp ROS-DNA (2.5 ng/ml) and inhibitors used 
were DNA isolated from lymphocytes of various age groups. 
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inhibition observed in case of three serum samples was in the range of 42-64% by 
ROS-DNA (Fig. 46a,b), while two showed moderate, but higher inhibition than 
nDNA. One serum showed a higher recognition of nDNA (55% inhibition) than 
ROS-DNA (46%). The results point out conclusively a higher reactivity of antibodies 
in breast cancer sera towards oxidatively damaged DNA over unmodified native 
DNA. 
Among three sera from patients of lung cancer (two male and one female), 
two were found positive for reactivity towards nDNA and ROS-DNA. The other 
serum showed reactivity with both ROS-DNA and nDNA, with a greater preference 
for ROS-DNA. A maximum inhibition of 59% was seen with ROS-DNA and 43% 
with nDNA (Fig. 47a,b). One serum showed appreciable reactivity with ROS-DNA 
with a maximum inhibition of 58% (Fig. 47b). 
Five sera (all from females) were from patients suffering from cancer of the 
gall bladder. Out of these five, only two sera were found to be positive and showed 
higher affinity for ROS-DNA. The maximum inhibition was 3 7% and 40% 
(Fig. 47a,b). No appreciable recognition of nDNA was obtained with these two 
sera. Among three sera (all from males) of cancer of the urinary bladder, two 
showed higher recognition of native and ROS-DNA as competitors. One of the sera 
showed recognition of ROS-DNA to the extent of 30%, with negligible binding to 
nDNA, while the other showed a greater recognition of nDNA showing inhibition 
of 42% compared to 17% for ROS-DNA (Fig. 48 a,b). 
Four sera (three female and one male) were from patients with hepatocellular 
carcinoma with secondaries. Three of the sera showed positive recognition of ROS-
DNA and nDNA. All the three showed a higher reactivity with ROS-DNA over 
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Fig. 46. Detection of antibodies against nDNA and ROS-DNA in the sera of 
patients with breast cancer. The microtitre plates were coated with 
ROS-DNA (2.5 ^ig/ml). The inhibitors were nDNA (a) and ROS-DNA 
(b). The curves ( O ), ( # ), ( A ), ( A ), ( G ), ( 3 ) represent 
sera from different patients. 
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Fig. 47. Detection of antibodies against nDNA and ROS-DNA in the sera of 
patients with lung and gall bladder cancer. The microtitre plates were 
coated with ROS-DNA (2.5 fig/ml). The inhibitors were nDNA (a) and 
ROS-DNA (b). The curves ( O )> ( # ) represent sera from lung 
cancer and curves ( A ), ( A ) represent sera from cancer of the 
gall bladder. 
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Detection of antibodies against nDNA and ROS-DNA in the sera of 
patients with urinary bladder and hepatocellular cancer. The microtitre 
plates were coated with ROS-DNA (2.5 ^g/ml). Tbe inhibitors were 
nDNA (a) and ROS-DNA (b). The curves ( O ),( • ) represent sera 
of urinary bladder cancer and curves ( A ), ( • ), ( 3 ) represent 
sera of hepatocellular cancer. 
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nDNA (Fig. 48 a,b). Two among these three, showed maximum inhibitions of 36% 
and 37%, while the third showed a moderate inhibition of 28%. 
Three sera were collected from patients with carcinoma of the prostate. Two 
of the sera showed recognition of both nDNA and ROS-DNA. While one of the sera 
showed a higher preference for ROS-DNA (37% inhibition), the other recognized 
both nDNA and ROS-DNA, exhibiting equal inhibitions of 37% with both the 
competitors (Fig. 49a,b). The third serum showed no inhibition. The two sera that 
showed greater reactivity with the competitors, were from patients 60 and 70 years 
of age, while the third was of 45 years. 
One serum sample was from a patient with Hodgkin's lymphoma. The serum 
showed a strong binding to nDNA with a maximum inhibition of 53%, while its 
reactivity for ROS-DNA was lower, only to the extent of 30% (Fig. 49a,b). One 
serum of renal cell carcinoma showed a higher recognition for ROS-DNA (28% 
inhibition) over nDNA (11% inhibition) (Fig. 49a,b). One caecal cancer serum 
showed a high reactivity towards both nDNA and ROS-DNA. The preference for 
uDNA was much higher with an inhibition of 70%, while inhibition with ROS-DNA 
was lower to the extent of 48% (Fig. 49a,b). 
Sera from patients with rectal, ovarian, penis, stomach, bronchus cancer 
were negative showing little or no recognition for nDNA or ROS-DNA. The binding 
data of the cancer sera are summarized in Table 11. 
Probing Oxidative DNA Damage in Cancer Patients Using 
Monoclonal Antibody 
DNA was isolated from lymphocytes of cancer patients.The purity and 
concentration of the DNA preparations were ascertained by A^ ^^  and A^^^ 
measurements. The anti-ROS-DNA monoclonal antibody v/as used as a probe to 
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Fig. 49. Detection of antibodies against nDNA and R.OS-DNA in the sera of 
patients with cancer of prostate, Hodgkin's lymphoma, renal cell and 
caecum carcinoma. The microtitre plates were coated with ROS-DNA 
(2.5 ^g/ml). The inhibitors were nDNA (a) and ROS-DNA (b). The 
curves ( O )>( # ) represent sera of prostate cancer, while curves 
( A ) , ( • ) , ( 3 ) represent sera of Hodgkin's lymphoma, renal 
cell .and caecal carcinoma respectively.. 
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TABLE 11 
Antibodies Against Native DNA and ROS-DNA in Cancer Sera 
Type of Cancer No. of sera No. of sera Sera positive Sera positive Sera positive 
tested positive" for ROS-DNA for nDNA for both 
Breast 
Lung 
GaU bladder 
Urinary bladder 
Caecum 
Hepatocellular 
Hodgkin's lymphoma 
Prostate 
Renal cell 
Rectum/Ano-rectal 
Ovarian 
Penis 
Stomach 
Bronchus 
Rhabdomyosarcoma 
8 
3 
5 
3 
1 
4 
1 
3 
1 
4 
2 
1 
1 
1 
1 
6 
2 
2 
2 
1 
3 
1 
2 
1 
-
-
-
-
-
-
5 
1 
2 
1 
-
3 
-
1 
1 
-
-
-
-
-
-
'Sera were considered positive where inhibition achieved was >35-40%. 
The microtitre plates were coated v^th ROS-DNA (2.5 jig/ml). ITie inhibitors were nDNA 
and ROS-DNA. 
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detect oxidative damage to DNA from cancer patients. DNA isolated from normal, 
healthy individuals served as controls (Figs. 42,43). Immune complexes were made 
between isolated DNA and monoclonal antibody. Microtitre plates were coated 
with 400 bp ROS-DNA. 
DNA was isolated from three cancer patients with breast cancer. Two of the 
samples showed a high inhibition of monoclonal antibody binding to the coating 
antigen. One of them showed a maximum inhibition of 5 8% (Fig. 50), while the 
other showed a lower inhibition of 40% (Fig. 50). The third sample showed 
negligible inhibition of 23%. 
Another three DNA samples were from patients suffiering from lung cancer. 
One sample showed a high inhibition of monoclonal antibody activity to the extent 
of 53% (Fig. 51), while another sample showed moderate inhibition of 33% 
(Fig. 51). The third sample showed negligible inhibition of about 23%. 
DNA was isolated from two patients suffering from hepatocellular carcinoma. 
One of the two samples showed a high level of inhibition with the monoclonal 
antibody (46%) and the other showed a moderate inhibition of 30% (Fig. 52). Of the 
two DNA samples from cancer of the prostate, one showed a moderate inhibition of 
33%, while the other was not inhibitory (Fig. 53). Of the two DNA samples of 
cancer of the gall bladder, one was recognized by the monoclonal antibody to the 
extent that its activity was inhibited by 42% (Fig. 53). The other sample showed 
lower inhibition of 27% (Fig. 53). The binding data of the monoclonal antibody to DNA 
isolated from cancer patients is summarized in Table 12. These results demonstrate the 
presence of oxidative lesions in DNA of cancer patients and is being recognized 
efficiently by a monoclonal antibody having specificity for ROS-modified epitopes 
on nucleic acids. 
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Fig. 50. Inhibition of anti-ROS-DNA monoclonal antibody binding to 400 bp 
R O S - D N A by DNA isolated from lymphocytes of patients with breast 
cancer. Microtitre plates were coated with 400 bp ROS-DNA 
(2.5 fig/ml). The curves ( O ) , ( # ) , ( A ) represent DNA samples 
from different patients. 
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Fig. 51 . Inhibition of anti-ROS-DNA monoclonal antibody binding to 400 bp 
ROS-DNA by DNA isolated from lymphocytes of patients with lung 
cancer. Microtitre plates were coated with 400 bp ROS-DNA (2.5 \ig/ 
ml) The curves ( O ) , ( • ) , ( A ) represent DNA samples from 
different patients. 
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Inhibition of anti-ROS-DNA monoclonal antibody binding to 400 bp 
ROS-DNA by DNA isolated from lymphocytes of patients with 
hepatocellular cancer. Microtitre plates were coated with 400 bp 
ROS-DNA (2.5 ng/ml) The curves ( O X( • ) represent DNA 
samples from different patients. 
136 
0.01 
Fig. 53. 
0.1 1.0 
Inhibitor Concentration (>jg/inl) 
100 
Inhibition of anti-ROS-DNA monoclonal antibody binding to 400 bp 
ROS-DNAbyDNA isolated from lymphocytes of .patients with prostate 
cancer ( # ), ( A ) and cancer of the gall bladder ( O ), ( A )• 
Microtitre plates were coated with 400 bp ROS-DNA (2.5 \ig/ml) 
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TABLE 12 
Binding of Anti-ROS-DNA Monoclonal Antibody to DNA Isolated 
from Lymphocytes of Cancer Patients 
Type of Cancer Number of Number of samples Maximum percent 
samples positive' inhibition (at 20 ^g/n]l) 
Breast 58 
40 
Lung 
Hepatocellular 
Prostate 
Gall bladder 
3 
2 
2 
2 
53 
46 
42 
'luhibitions >40% were considered positive. 
The microtitre plates were coated with 400 bp ROS-DNA (2.5 ^g/ml) and inhibitors were 
DNA isolated from lymphocytes of patients with various types of cancer. 
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Reactive oxygen species (ROS) are continuously formed in living cells 
as a consequence of normal metabolism and have been implicated in a 
number of human degenerative diseases including cancer and aging (Halliwell, 
1994; Knight, 1995; Loft and Poulsen, 1996). These highly reactive 
electrophilic species, can not only permanently damage cells by reacting 
with nucleic acids, proteins and lipids, but may also lead to cell death. It is 
reported that ROS modify approximately 10,000 nitrogenous bases in DNA 
per cell per day (Ames et al., 1991). Many of these lesions are however 
repaired. Accumulation of some unrepaired lesions may be part of the 
changing pattern of gene expression that occurs with aging (Edgington, 
1994). 
Amongst a variety of ROS, the hydroxyl radical is the most potent, 
reacting with very high rate constants with a wide range of biological 
substances (Hutchinson, 1985; Pryor, 1988). In vivo, hydroxyl radicals are 
formed via ionizing radiations (Breen and Murphy, 1995) or through Haber-
Weiss or Fenton reactions (Mello-Filho and Meneghini, 1984a; Aruoma ei al., 
1991). 
DNA is the most susceptible macromolecule for hydroxyl radical 
attack and damage occurs at the site where the reduced metal bound to DNA 
reacts with hydrogen peroxide (Czapski, 1984; Hutchinson, 1985; Halliwell 
and Gutteridge, 1989). Oxidative damage to DNA includes a range of 
specifically oxidized purine and pyrimidine bases and strand breaks 
(Dizdaroglu, 1994; Breen and Murphy, 1995). The comimon modified bases 
include 8-hydroxyguanine, thymine glycol, 5-hydroxymethyluracil, 8-
oxoadenine etc. (Floyd, 1990; Dizdaroglu, 1994). In addition to modified 
139 
bases, modified sugars have also been identified (Dizdaroglu, 1994). 
Cancer and aging, the two biological consequences with the most 
complex etiology, has been implicated in free radical induced damage to 
DNA (Ames et al., 1993a; 1995). Despite enzymatic repair and other defences, 
continuous ROS damage and division of cells with unrepaired or misrepaired 
lesions lead to mutations. If these relate to critical genes such as oncogenes 
or tumor suppressor genes, initiation and/or progression of cancer can occur. 
In these studies, ROS or the hydroxyl radical generated by the irradiation 
of hydrogen peroxide by 254 nm UV light caused extensive damage to DNA, 
leading to single strand breaks and base modifications. The absorption of 
DNA decreased at 260 nm after ROS modification compared to the native 
double stranded analogue. The hypochromicity in ROS-DNA could be a 
result of modification of the nitrogenous bases. Treatment of DNA with 
hydrogen peroxide or UV light alone did not result in any significant change 
in the spectral properties. 
Thermal denaturation of ROS-DNA showed a decrease in Tm to the 
extent of 6.5°C and H ' C in case of ROS-modified 400 bp DNA, indicating 
the presence of single stranded regions in the modified DNA, as also a 
partial destruction in its secondary structure. Base stacking as well as 
hydrogen bonding are involved in stabilizing the native structure of DNA 
and their disruption by high temperature favours denaturation (Casperson 
and Voss, 1983; Thomas, 1993). The results of lowered Tm in ROS-DNA, 
therefore, point towards the destabilization of these interactions and 
consequent helix disruption. Structural alterations are caused in ROS-DNA 
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due to s imul taneous strand scission, generat ion of single s t randed regions 
and disrupt ion of hydrogen bonding. 
The g e n e r a t i o n of s i n g l e s t r a n d b r e a k s w a s s t u d i e d by 
hydroxyapat i te column chromatography. Hydroxyapati te discr iminates nucleic 
acids endowed with different secondary s t ruc tu res , with r igid, ordered 
s t ruc tu res having more affinity for the matrix than flexible, d isordered ones 
(Bernard i , 1965; 1969). Unmodified native and 400 bp DNA eluted as a 
single peak with 250 mM Na-K phosphate buffer, indicat ing their double-
s t randedness . In con t ras t , ROS-DNA (both native and 400 bp) eluted as two 
peaks - one minor and one major. The minor peak eluted at lower ionic 
s t rength of 125 mM of the buffer, const i tu t ing abjout 20% of to ta l ROS-DNA 
applied to the column, while the major fraction eluted with buffer of higher 
ionic s t rength accompanied by a shift in the peak posi t ion . The minor fraction 
may be a t t r ibuted to the generat ion of single strand reg ions and shift in peak 
pos i t ion , to weaker in terac t ion of ROS-DNA with the matr ix as a consequence 
of local pe r tu rba t ions in the secondary s t ructure of DNA. 
The presence of single s t randed regions in DNA following modification 
with hydroxyl radical was further observed by the sedimenta t ion profi les of 
n a t i v e and R O S - D N A in an a l k a l i n e s u c r o s e d e n s i t y g r a d i e n t . On 
u l t racent r i fuga t ion , nDNA showed a single distinct species and sedimented 
sharply, whereas ROS-DNA showed a diffused sedimentat ion profi le. The 
data indicates random dis t r ibut ion of single strand breaks which appear as 
f ragments and sediment in diffused manner, in cont ras t to nDNA. These 
resu l t s are in accordance to earl ier repor t s of hydroxyl radical as a mediator 
141 
of single strand breaks (Meneghini and Hoffmann, 1980; Mello-Filho and 
Meneghini, 1984b; Meneghini, 1988). 
Earlier studies demonstrate structural alterations in DNA following 
damage by various agents and may be large enough to be recognized by 
single strand specific nucleases (Kato and Fraser, 1973; Slor and Lev, 1973; 
Shisido and Ando, 1974; Yamasaki et al., 1977). Native and ROS-DNA were 
subjected to nuclease SI digestion, in order to confirm the generation of 
single strand breaks. The data shows a total digestion of ROS-DNA on 
t rea tment with nuclease S I , while nDNA remain undigested. These 
observations clearly demonstrates, that, sufficient distortions are caused in 
the helical structure of DNA by hydroxyl radical rendering it susceptible to 
digestions by single-strand specific nuclease SI. 
The hydroxyl radical was also found to produce base modifications in 
DNA. In case of both, ROS-DNA and 400 bp ROS-DNA, thymine was 
modified maximally, followed by guanine. These results are consistent with 
earlier studies which demonstrate greater susceptibility of thymine and 
guanine to modification by hydroxyl radical (Demple and Linn, 1982; 
Hutchinson, 1985; Yamamoto and Kawamishi, 1989; Rosen et al., 1996). 
ROS-DNA was found to be a potent immunogen, inducing high titre 
polyclonal antibodies in goat. Native DNA per se is a poor immunogen 
(Madaio et al., 1984; StoUar, 1986), whereas, double stranded RNA, RNA-
DNA hybrids, double helical polydeoxyribonucleotides, DNA modified with 
drugs, hormones, chromatin or DNA in complexes with DNA binding proteins 
induce antibodies ( Stollar, 1973; 1975; 1986; Anderson et al., 1988a; Desai 
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eta/., 1993; Moinuddin and Ali, 1994; Arjumand et al., 1995; Theofi lopoulos , 
1995). These s tudies demonstra ted that the ant igenic s t imulus for genera t ion 
of an t ibodies against DNA involves a substance other than DNA or a 
conformat ional var iance from the B-form (Burl ingame et al., 1993; Mohan et 
al., 1993). 
The antigenic specificity of affinity purified ant i -ROS-DNA IgG showed 
a s t rong concen t ra t ion dependent binding to ROS-DNA. These resu l t s were 
confirmed by inhibit ion ELISA. The concent ra t ion of immunogen requi red 
for 50% inhibit ion of IgG binding to immunogen was observed to be 4 ^ g / 
ml. In addi t ion , the induced ant ibodies showed a considerable recogni t ion of 
na t ive DNA. This cross- react iv i ty may be d u e . to the recogni t ion of an 
ant igenic determinant common to both ROS- and nDNA aiad could possibly be 
the suga r -phospha te backbone (Lafer et al., 1981 ; Rauch et al., 1985). 
Compet i t ion immunoassay using adenine and thymine showed negligible 
recogn i t ion of polyclonal IgG as did ROS-modified adenine. In cont ras t , 
ROS-thymine showed substantial inhibit ion in a compet i t ion assay. Similar 
resu l t s were obtained with poly (dA) , poly(dT) and their ROS-modified 
forms. ROS-poly (dT) showed a high inhibition of IgG binding to immunogen. 
Both ROS-thymine and ROS-poly(dT) showed 53% and 59% inhibit ion of 
ant ibody binding to ROS-DNA respect ively. The data clearly indica tes the 
r ecogn i t ion of ep i topes generated on thymine and poly(dT) after ROS-
modif icat ion. Earl ier studies suggested thymine moiety to be par t icular ly 
suscept ib le to hydroxyl radical modification (Hutchinson, 1985; Breen and 
Murphy, 1995). It can therefore be surmised that ROS-modified thymine may 
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cause changes in DNA, and consequently alter its immunogenicity and the 
consequent generation of antibodies. Earlier reports on antibodies specificity 
against UV-irradiated DNA (Levine e/a/ . , 1966; Eggset e^ o/., 1987; Herbert 
et al., 1994) show preferential recognition of thymine moieties and (6-4) 
photoproducts of thymine on (Mori et al., 1991) nucleic acids and 
oligonucleotides. The antibodies generated against ROS-DNA, although 
showing recognition and binding of ROS-modified epitopes, demonstrated 
lesser re la t ive affinities as evident from the requi rement of high 
concentrations of ROS-thymine and ROS-poly(dT) to achieve 50% inhibition 
of anti-ROS-DNA antibody binding to ROS-DNA. 
The above results indicate that the polyclonal antibodies may not be 
very useful as probes to detect oxidative damage to DNA. Monoclonal 
antibodies were raised against ROS-DNA and was of IgGl isotype. The 
monoclonal antibody showed a high recognition of the immunogen (400 bp 
ROS-DNA) as only 4.4 pg/ml was required for 50% inhibition of antibody 
binding to antigen in competition ELISA. An even greater inhibition with 
lower inhibitor concentrations for 50% inhibition was observed with ROS-
DNA and slightly lowered inhibition with 200 bp ROS-DNA. This suggests 
that increasing chain length of ROS-modified DNA contains repeating units 
of antigenic determinants and a consequent increase in the binding of the 
antibody. The monoclonal antibody also showed a degree of cross-reactivity 
with nDNA, but the relative affinity of the antibody was low as compared 
to the inhibitors which contained ROS-modified epitopes. Cytosine, ROS-
cytosine, ROS-poly(dA), poly(dG), guanine, RNA and poly(dA) were poor 
inhibitors of antibody binding to the antigen. While guanine was a poor 
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inhibitor, its ROS-modified form, ROS-guanine was an effective inhibitor of 
the antibody binding. The single-stranded RNA homopolymer, poly(G) was 
not an effective inhibitor, but its modified form, ROS-poly(G) showed a high 
inhibitory potential. These results with ROS-guanine and ROS-poly(G) 
indicate that the antibody binds to the ROS-modified epitopes on guanine, 
although to a low extent. In contrast to the above inhibitors, ROS-thymine, 
ROS thymidine and ROS-poly(dT) showed substantial inhibition of antibody 
activity to the extent of 66.5%, 57% and 68% respectively. In contrast, their 
unmodified forms showed low levels of inhibition of antibody activity. 
Earlier reports demonstrated thymine to be particularly susceptible to 
modification by OH (Hutchinson, 1985; Dizdaroglu and Bergtold, 1986; 
Breen and Murphy, 1995) generating products Such as 5,6-dihydroxy-5-6-
dihydrothymine (thymine glycol), 5-hydroxy-5-6-dihydrothymine or 6-
hydroxy-5-6-dihydrothymine. The results of the study of the fine antigenic 
specificity of the monoclonal antibody clearly demonstrates the preferential 
recognition of ROS-modified epitopes. The data, also indicates some degree 
of cross-reactivity of the monoclonal antibody. This could be due to the 
polyspecificity of antibodies against any form of DNA (Lafer et al., 1981; 
Rauch et al., 1985). 
Aged people are pa r t i cu la r ly suscep t ib l e to in fec t ions , 
lymphoprol i fera t ive disorders and increased frequency of cer ta in 
autoantibodies (Goodwin et al., 1982; Hijmans et al., 1984; Manoussakis et 
al., 1987; 1990). The phenomena clearly indicate immunoregulatory 
perturbations during senescence, however, its nature is obscure (Tomer and 
Shoenfeld, 1988; Talor and Rose, 1991; Hartwig, 1992). 
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Even less is known about the pathological and physiological significance 
of age-related autoantibodies. They have been associated with shortened 
survival in humans and with the spontaneous development of organ-specific 
autoimmune lesions in aged non-autoimmune mice (Hayashi et al., 1989; 
Mariotti et al., 1992). Such natural autoantibodies are also seen in humans of 
all ages and may play an immunoregulatory role (Avrameas, 1991). Numerous 
studies report the presence of anti-nuclear antibodies in aged population (60-
80 years) (Seligmann et al., 1965; Moulias et al., 1984) and persons aged 
over 70 have increased levels of anti-DNA antibodies (Schuller et al., 1981) 
and anti-ssDNA antibodies (Kasjanov et al., 1984). 
The presence of antibodies reactive to double stranded DNA and ROS-
DNA in sera of young and aged population was studied by competition 
ELISA. Competition ELISA data of normal human sera from age below 35 
years and 35-49 years show no reactivity towards either native or ROS-
DNA. These results are consistent with earlier reports (Moulias et al., 1984; 
Xavier et al., 1995). These age groups are considered as the control group. 
In the age group 50-59 years, one sample out of nine showed strong reactivity 
with ROS-DNA, while three sera were moderately reactive. Sera from 
normal individuals over 60 years of age, showed a strong recognition and 
binding of both native and ROS-DNA. Earlier reports showed about 3.8% 
anti-nuclear antibody (ANA) prevalence in young age group and 10-37% in 
the elderly (Talor and Rose, 1991). Other studies show that the main 
increase in ANA expression occurs in the sixth and seventh decade of life 
(Hooper et al., 1972). Xavier et al. (1995) have also shown higher levels of 
ANA in the aged and especially in high titres, these antibodies have a 
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persistent character. Higher frequencies of anti-DNA and anti-ssDNA 
antibodies in aged individuals has also been reported (Hasselbacher and 
Leroy, 1974; Rubin and Carr, 1979; Schuller et al., 1981; Goto et al ., 1982; 
Kasjanov et al., 1984; Xavier et al., 1995). It is likely that the high frequency 
of autoantibodies observed in the elderly is atleast partly associated with 
diseases appearing with age and partly on immunological senescence. Another 
hypothesis is the function of the thymus and the aging paradox (Rose, 1994). 
Since the thymus involutes asymmetrically, a clonal imbalance is generated 
with aging as the proportion of autoantigen-specific helper/inducer T cells 
increases relative to the number of autoantigen specific regulatory T cells. 
This leads to the increase in levels of autoantibodies with age. Also 
nonspecific immunoregulatory mechanisms increase with age. As the thymic 
cortex atrophies, the response to foreign antigens declines, whereas the 
response to self-antigens rise, generating the age related increase in 
autoantibodies. 
Genomic DNA was isolated from the lymphocytes of normal human 
individuals of different age groups and the presence of oxidative damaged 
lesions was probed using the anti-ROS-DNA monoclonal antibody. No 
appreciable binding or inhibition was seen with DNA isolated from 
individuals below 35 years and 35-49 years. However, in the age group over 
60 years, four DNA isolates showed high inhibitions of monoclonal antibody 
binding ranging from 49-70%, two were moderately inhibitory, while the 
remaining five samples showed negligible inhibition of antibody binding. 
These data clearly indicate the presence of oxidative lesions in DNA from 
normal healthy elderly individuals and are being efficiently recognized by 
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the monoclonal ant ibody shown to have greater preference for oxidat ively 
damaged epi topes on nucleic acids. 
The free radical theory of aging suggests that ROS inflict molecular 
damage , some of which is i r reparable and accumulates with age, thereby 
causing phenotypic changes associated with aging (Harman, 1962). The 
theory further sugges ts that in the context of specific pa tho logica l changes, 
oxida t ive stress may lead to cellular damage manifested as disease processes . 
Al though many in vivo ant i - radical defense systems exist , there is nevertheless 
a constant low level of oxygen radical induced non-repaired damage to cellular 
components including p ro te ins , l ipids and in par t icular DNA (Pacifini and 
Davies , 1991). The accumulat ion of DNA damage is an impor tant feature , as 
it leads to a decrease in mRNA expression or premature te rminat ion affecting 
prote in synthesis and an overal l decline in cellular functions (Holmes et al., 
1992). Several s tudies indicate an age-related increase in s ingle-s t randed 
DNA, s ingle-strand breaks and /or alkali-labile sites in a var ie ty of t issues 
(Mass ie et al., 1972; Mullaart et al., 1990; Singh et al., 1990; 1991 ; Holmes 
etal., 1992; Higami e / a / . , 1994). An age-related de ter iora t ion in DNA repair 
ac t iv i ty and/or increases in DNA vulnerabil i ty to free radica ls and related 
oxidants are considered to be responsible for the age re la ted increase in 
DNA damage (Rao et al., 1990a,b). Such accumulated damage can lead to 
muta t ions disrupting the cell by al ter ing gene regulat ion or thei r p roduc ts and 
prevent DNA repl icat ion leading to cell death (Ames, 1989b). 
DNA damage induced by numerous genotoxic agents is studied by a 
var ie ty of methods including gas chromatography/mass spec t roscopy (GC-
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MS), HPLC (Dizdaroglu and Gajewski, 1990) and electrochemical detection 
(EC). All these methods detect oxidized hases and nucleotides, such as 8-
oxodG. In addition, nucleotides are also detected by "P-postlabelling (Wilson 
et al., 1993) and radiometric detection. Immunochemical methods involving 
antibodies to specific DNA base modifications, carcinogen-DNA adducts 
have contributed to studies of DNA damage, repair and risk assessment 
biomonitoring ( Leadon and Hanawalt, 1983; Park et al., 1992; Chao et al., 
1994; Musarrat and Wani, 1994; Venkatachalam and Wani, 1994). The 
monoclonal antibody against ROS-DNA reported in this thesis was therefore 
used as a reagent to probe for oxidative DNA damage to the human genomic 
DNA. 
The data on the use of the monoclonal antibody as a probe, clearly 
indicates the recognition and reactivity of DNA isolated from the aged 
population, while showing little reactivity to DNA from the young population. 
The data clearly is in concurrence with earlier reports of higher incidence 
and susceptibility of oxidative DNA damage among the elderly over the 
younger population (Singh et al., 1990; 1991; Holmes et al., 1992). The 
results also demonstrate a higher incidence of serum antibodies reactive 
towards native and ROS-DNA with a greater recognition for oxidatively 
damaged DNA. In this case, it may be suggested that free radical damage to 
DNA in vivo, particularly in the aged, alters its antigenicity and stimulates 
an immune response against modified DNA. The autoantibodies generated 
may be cross-reactive to nDNA. This could be a possible source of serum 
antibodies in the elderly reactive to nDNA and ROS-DNA. 
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The presence of autoant ibodies react ive t owards nDNA and ROS-DNA 
in sera of pa t ien t s with cancer was also studied . The study consis ted of 39 
sera from pa t ien t s with var ious types of mal ignancies . Twenty sera showed 
posi t ive recogni t ion and binding to nDNA or ROS-DNA. Among these 
twenty , fourteen showed a higher react ivi ty toward modified DNA, one to 
nDNA and five sera showed almost equal recognition of nDNA and ROS-DNA. 
The rest of the sera showed l i t t le or no recogni t ion of either of the nucleic 
acids. 
Increased levels of circulat ing ant ibodies and au toan t ibod ies have 
been repor ted in sera of pa t ien ts with mal ignancies (Tannenberg et al., 
1973; Whi tehouse , 1973; Wasserman et al., 1975; Anderson et al., 1988b; 
Chagnaud et al., 1992; Faiderbe et al., 1992; Becker et al., 1994). At tempts 
have been made to establish the molecular identi ty of the au toan t igens that 
are t a rge t s of au toan t ibodies in cancer without much success . Elevated l i t res 
of ant i -nuclear ant ibodies (ANA) upto 27% in cancer sera have been repor ted 
( Bunham, 1972; Ze ronsk i et al., 1972). The c l in ica l s ignif icance of 
au toan t ibod ies in cancer is unclear , al though the p resence of ANA might 
indicate a worse p rognos i s or a more frequent r ecu r rence of breas t cancer 
(Wasserman et al., 1975; Turnbull et al., 1978). In pa t ien ts with hepatocel lular 
carcinoma (HCC) , a high prevalence of ANA has been r epo r t ed (Kiyosawa 
et al., 1985; Imai et al., 1992; 1993). 
The data p resen ted here clearly indicates the p resence of c i rcula t ing 
ant ibodies in cancer sera reactive to ROS-DNA and nDNA. A high p ropor t ion 
of sera (6 out of 8) from breast cancer showed reac t iv i ty to the ant igens . 
Five of these sera showed a higher binding to ROS-DNA. It has been well 
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accepted that ROS damage to DNA plays a fundamental role in carcinogenesis, 
particularly of the breast cancer (Malins and Haimanot, 1991; Malins et al., 
1996). Therefore, ROS-modification of DNA might be the contributory 
factor in the induction and elevated levels of the circulating antibodies 
primarily against ROS-DNA but cross-reacting with nDNA. 
Lung and hepatocellular cancers are also strongly correlated with 
oxidative DNA damage (McElride et al., 1991; Olinski et al., 1992). Tobacco 
smoke may involve both an increase in mitochondrial production of ROS as 
also the presence of ROS and ROS-generating compounds in smoke and have 
the potential to cause DNA damage (Leanderson and Tagesson, 1990, 1992). 
Hepatocellular carcinoma is actively associated with chronic viral hepatitis 
B and C and this results in the generation of ROS due to the presence of 
inflammation (Cotran et al., 1989; Cerruti and Trump, 1991). Hence, oxidative 
damage to DNA is postulated to be a major event in the development of 
these cancers. It would be interesting to note that two sera from patients with 
lung cancer reactive to ROS-DNA, were having a history of smoking of over 
two decades and supports for strong oxidative stress //; vivo. The oxidative 
damage to DNA might once again be the major factor for the circulating 
antibodies reactive to ROS-DNA. Moreover, all the four patients with 
hepatocellular carcinoma also had chronic hepatic infections which could 
again explain the onset of cancer as described earlier (Beasley, 1988; 
Stein, 1991). Among these four sera, three showed a higher binding to ROS-
DNA. Similar results were obtained with sera from cancer of the gallbladder 
(2/5), urinary bladder (1/2), prostate (1/2) and renal cell carcinoma (1/1). In 
all these sera, preferential reactivity with ROS-DNA over nDNA was observed. 
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Among these 20 cancer sera that showed substantial reactivity to native 
and ROS-DNA, 10 were from patients over 50 years of age. Three of the six 
sera from breast cancer were from patients in the age 52-58 years and are 
burdened with immense oxidative stress compared to individuals with normal 
breast (Musarrat et al., 1996). The age of an individual has been recognised 
as a major risk factor in the development of breast cancer (Fleming and 
Fleming, 1994). Similarly, the two sera of lung cancer, showing binding to 
ROS-DNA were from males over 60 years of age which were smokers. 
Patients with hepatocellular, urinary bladder and gall bladder cancers were 
generally in the lower age group. Prostate cancer sera showed reactivity for 
ROS-DNA as well as nDNA and were from patients over 60 years. This age 
group is usually associated with prostate cancer. However, the paucity of 
known chemical agents associated with this type of cancer and absence of any 
apparent environmental or occupational risk factors suggest that prostate 
cancer is associated with endogenous cellular processes (Feig et al., 1994; 
Olinski et al., 1995). The most plausible candidates for endogenously formed 
genotoxins that accumulate in aged are the ROS. 
The data clearly supports the notion of ROS damage to DNA and thus 
altering the immunogenicity of DNA, leading to the generation of antibodies. 
The above statement is supported by the observation that circulating 
antibodies bind preferentially to ROS-DNA over nDNA. 
DNA was isolated from lymphocytes of patients with various types of 
cancers. The monoclonal anti-ROS-DNA antibody was subsequently used as 
an immunochemical probe to detect oxidative damage in these DNA 
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isolates by competition ELISA. The data shows that five out of a total of 
twelve DNA samples inhibited monoclonal antibody binding to ROS-DNA. 
Two DNA samples out of three from patients with breast cancer showed 
inhibition of monoclonal anti-ROS-DNA antibody binding to ROS-DNA to the 
extent of 58% and 40%. Hydroxyl radical mediated damage to DNA, in 
particular to the nitrogenous bases has attained centre stage as a primary 
cause of cancer (Floyd, 1990; Malins, 1993; Halliwell, 1994). Two major 
mutagenic lesions, are 8-hydroxyadenine and 8-hydroxyguanine are 
characteristically elevated in DNA from breast cancer patients and are 
associated with heightened risk of cancer (Malins et al., 1996; Musarrat et 
al., 1996). The recognition of DNA from breast cancers by the monoclonal 
antibody may be attributed to the presence of such oxidative lesions. 
Cigarette smokers are extremely vulnerable to oxidative stress and 
high urinary excretion of 8-oxodG in smokers has been reported ( Inoue et 
al., 1993; Loft et al., 1994). Studies in cell cultures reiterated the above 
observation (Leanderson and Tagesson, 1990; 1992). One isolated DNA 
sample out of three from lung cancer showed a high reactivity with the 
monoclonal antibody indicating the presence of oxidative lesions, which in 
all probabilities could have been caused by smoking. 
One sample out of two from hepatocellular carcinoma also showed a 
high recognition of monoclonal antibody. Hepatocellular carcinoma is actively 
associated with DNA damage and mutations by aflatoxin (Loeb and Preston, 
1986) or viral hepatitis infections leading to free radical generation (Chirsari 
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et a!., 1989; Shimoda et al., 1994). One DNA isolate from cancer of the gall 
bladder also showed binding to the monoclonal antibody. 
These results demonstrate the presence of ROS-induced DNA damage 
in cancer patients which might play an active part in the progression of 
disease mediated by mutations and subsequent neoplastic transformation of 
the cell. The studies also clearly demonstrate the use of the monoclonal anti-
ROS-DNA antibody as an alternative immunochemical probe to detect oxidative 
lesions in DNA. Earlier studies report the use of antibodies to specific DNA 
base alterations, carcinogen-DNA adducts or to UV-DNA (Leadon and 
Hanawalt, 1983; Kasai and Nishimura, 1986, Park et al., 1992; Herbert et al., 
1994 ; Wani et al., 1994). Only a few of these antibodies have been utilised 
in the analysis of DNA in intact cells. Some of these were unable to detect 
their target epitopes in macromolecular DNA (Park et al., 1992). In contrast, 
the monoclonal anti-ROS-DNA antibody clearly shows a greater preference 
for ROS-modified epitopes and cau be used as a probe to detect oxidative 
damage to DNA in cells and tissues under oxidative stress. Further studies 
might elucidate their significance in the early detection of oxidative DNA 
damage and thus be of help in cancer diagnosis and therapy. 
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